

PATENT ASSIGNMENT

Electronic Version v1.1
Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	Patent and Trademark Security Agreement
CONVEYING PARTY DATA	
Name	Execution Date
Biovail Laboratories International SRL	06/09/2009
RECEIVING PARTY DATA	
Name:	J.P. Morgan Chase Bank, N.A., Toronto Branch, as Administrative Agent
Street Address:	200 Bay Street
Internal Address:	Suite 1800
City:	Toronto
State/Country:	CANADA
Postal Code:	M5J 2J2
PROPERTY NUMBERS Total: 38	
Property Type	Number
Application Number:	11451496
Application Number:	11834848
Application Number:	11930644
Application Number:	11751768
Application Number:	11766239
Application Number:	11766251
Application Number:	11774109
Application Number:	11751785
Application Number:	11755946
Application Number:	11759413
Application Number:	11762368
Application Number:	11762343
Application Number:	11762820
Application Number:	11762840

CH \$1520.00 11451496

500884152

PATENT
REEL: 022813 FRAME: 0195

Application Number:	11766213
Application Number:	11475252
Application Number:	11993723
Application Number:	10933479
Application Number:	11928908
Application Number:	10517809
Application Number:	12328828
Application Number:	12169852
Application Number:	10370109
Application Number:	11952343
Application Number:	10657752
Application Number:	10309193
Application Number:	10771987
Patent Number:	5529791
Patent Number:	5288505
Patent Number:	6143327
Patent Number:	6096341
Application Number:	10556492
Patent Number:	5286497
Patent Number:	5470584
Patent Number:	5439689
Patent Number:	7108866
Patent Number:	6676966
Application Number:	12360673

CORRESPONDENCE DATA

Fax Number: (617)227-4420

Correspondence will be sent via US Mail when the fax attempt is unsuccessful.

Phone: 6172390310

Email: jdavis@eapdlaw.com

Correspondent Name: Jessica Davis

Address Line 1: 111 Huntington Avenue

Address Line 2: Edwards Angell Palmer & Dodge LLP

Address Line 4: Boston, MASSACHUSETTS 02199

ATTORNEY DOCKET NUMBER:	224825.0051
-------------------------	-------------

NAME OF SUBMITTER:	Jessica Davis
--------------------	---------------

Total Attachments: 64

source=Patent and Trademark Agmt#page1.tif
source=Patent and Trademark Agmt#page2.tif
source=Patent and Trademark Agmt#page3.tif
source=Patent and Trademark Agmt#page4.tif
source=Patent and Trademark Agmt#page5.tif
source=Patent and Trademark Agmt#page6.tif
source=Patent and Trademark Agmt#page7.tif
source=Patent and Trademark Agmt#page8.tif
source=Patent and Trademark Agmt#page9.tif
source=Patent and Trademark Agmt#page10.tif
source=Patent and Trademark Agmt#page11.tif
source=Patent and Trademark Agmt#page12.tif
source=Patent and Trademark Agmt#page13.tif
source=Patent and Trademark Agmt#page14.tif
source=Patent and Trademark Agmt#page15.tif
source=Patent and Trademark Agmt#page16.tif
source=Patent and Trademark Agmt#page17.tif
source=Patent and Trademark Agmt#page18.tif
source=Patent and Trademark Agmt#page19.tif
source=Patent and Trademark Agmt#page20.tif
source=Patent and Trademark Agmt#page21.tif
source=Patent and Trademark Agmt#page22.tif
source=Patent and Trademark Agmt#page23.tif
source=Patent and Trademark Agmt#page24.tif
source=Patent and Trademark Agmt#page25.tif
source=Patent and Trademark Agmt#page26.tif
source=Patent and Trademark Agmt#page27.tif
source=Patent and Trademark Agmt#page28.tif
source=Patent and Trademark Agmt#page29.tif
source=Patent and Trademark Agmt#page30.tif
source=Patent and Trademark Agmt#page31.tif
source=Patent and Trademark Agmt#page32.tif
source=Patent and Trademark Agmt#page33.tif
source=Patent and Trademark Agmt#page34.tif
source=Patent and Trademark Agmt#page35.tif
source=Patent and Trademark Agmt#page36.tif
source=Patent and Trademark Agmt#page37.tif
source=Patent and Trademark Agmt#page38.tif
source=Patent and Trademark Agmt#page39.tif
source=Patent and Trademark Agmt#page40.tif
source=Patent and Trademark Agmt#page41.tif
source=Patent and Trademark Agmt#page42.tif
source=Patent and Trademark Agmt#page43.tif
source=Patent and Trademark Agmt#page44.tif
source=Patent and Trademark Agmt#page45.tif
source=Patent and Trademark Agmt#page46.tif
source=Patent and Trademark Agmt#page47.tif
source=Patent and Trademark Agmt#page48.tif
source=Patent and Trademark Agmt#page49.tif
source=Patent and Trademark Agmt#page50.tif
source=Patent and Trademark Agmt#page51.tif
source=Patent and Trademark Agmt#page52.tif
source=Patent and Trademark Agmt#page53.tif

source=Patent and Trademark Agmt#page54.tif
source=Patent and Trademark Agmt#page55.tif
source=Patent and Trademark Agmt#page56.tif
source=Patent and Trademark Agmt#page57.tif
source=Patent and Trademark Agmt#page58.tif
source=Patent and Trademark Agmt#page59.tif
source=Patent and Trademark Agmt#page60.tif
source=Patent and Trademark Agmt#page61.tif
source=Patent and Trademark Agmt#page62.tif
source=Patent and Trademark Agmt#page63.tif
source=Patent and Trademark Agmt#page64.tif

PATENT AND TRADEMARK SECURITY AGREEMENT

THIS PATENT AND TRADEMARK SECURITY AGREEMENT (as it may be amended or modified from time to time, the "Agreement"), is entered into as of June 9, 2009 (the "Effective Date"), by and between Biovail Laboratories International SRL, an entity continued under the laws of Barbados (the "Grantor") and JPMorgan Chase Bank, N.A. Toronto Branch, in its capacity as administrative agent (the "Administrative Agent") for the lenders from time to time party to the Credit Agreement referred to below (collectively, the "Lenders").

RECITALS

A. Biovail Corporation, a corporation continued under the federal laws of Canada (the "Borrower"), the Administrative Agent, and the Lenders are entering into a Credit Agreement dated as of the date hereof (as the same may be amended or modified from time to time, the "Credit Agreement") and the Grantor is entering into a Guarantee and Indemnity Agreement dated as of the date hereof in favor of the Administrative Agent for the benefit of the Finance Parties (as defined in the Credit Agreement) to guaranty the Obligations of the Borrower under the Credit Agreement. The Grantor is entering into this Agreement in order to induce the Finance Parties to enter into and extend credit to the Borrower under the Credit Agreement. All capitalized terms used herein and not otherwise defined shall have the meanings assigned to such terms in the Credit Agreement.

B. The Grantor is the owner of the Pledged Collateral (as defined herein) which on the schedules attached hereto is designated as being owned by the Grantor.

C. This Agreement is given by the Grantor in favor of the Administrative Agent for the benefit of the Finance Parties to secure the payment and performance of all of the Secured Obligations.

AGREEMENT

NOW, THEREFORE, in consideration of the foregoing premises and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Grantor and the Administrative Agent, on behalf of the Finance Parties, hereby agree as follows:

1. Grant of Security Interest. To secure the prompt and complete payment and performance of the Secured Obligations, the Grantor hereby pledges, assigns and grants to the Administrative Agent for itself and for the ratable benefit of the Finance Parties a continuing security interest in all of the Grantor's right, title and interest, whether now existing or hereafter acquired, in and to the following property (all of which will be collectively referred to as the "Pledged Collateral"):

(a) any and all patents and patent applications, including, without limitation, the patents, patent applications and licenses listed on Schedule A hereto, along with: (1) all inventions and improvements described and claimed therein; (2) all reissues, divisions, continuations, renewals, extensions, and continuations-in-part thereof; (3) all income, royalties, damages, claims, and payments now or hereafter due or payable under and with respect thereto, including, without limitation, damages and payments for past and future infringements thereof; (4) all rights to sue for past, present, and future infringements thereof; and (5) all rights corresponding to any of the foregoing throughout the world (collectively, "Patents");

(b) all trademarks (including service marks), trade names, trade dress, trade styles, and the registrations and applications for registration thereof and the goodwill of the business symbolized by the foregoing, including, without limitation, the registrations, applications, unregistered trademarks,

service marks and licenses listed on Schedule B hereto, along with: (1) all licenses of the foregoing, whether as licensee or licensor; (2) all renewals of the foregoing; (3) all income, royalties, damages, and payments now or hereafter due or payable with respect thereto, including, without limitation, damages, claims, and payments for past and future infringements thereof; (4) all rights to sue for past, present, and future infringements of the foregoing, including the right to settle suits involving claims and demands for royalties owing; and (5) all rights corresponding to any of the foregoing throughout the world (collectively, "Trademarks");

(c) the entire goodwill of the Grantor's business and other general intangibles (including know-how, trade secrets, customer lists, proprietary information, inventions, domain names, methods, procedures and formulae) connected with the use of and symbolized by Trademarks of the Grantor;

(d) any other intellectual property of the Grantor; and

(e) all Proceeds (as defined under the Uniform Commercial Code as in effect in the State of New York (the "UCC") or other relevant law) of any of the foregoing, and in any event including, without limitation, any and all (1) proceeds of any insurance, indemnity, warranty or guaranty payable to the Administrative Agent or to the Grantor from time to time with respect to any of the Pledged Collateral, (2) payments (in any form whatsoever) made or due and payable to the Grantor from time to time in connection with any requisition, confiscation, condemnation, seizure or forfeiture of all or any part of the Pledged Collateral by any Governmental Authority (or any person acting on behalf of a Governmental Authority), (3) instruments representing amounts receivable in respect of any Patents or Trademarks, (4) products of the Pledged Collateral and (5) other amounts from time to time paid or payable under or in connection with any of the Pledged Collateral.

2. No Release. Nothing set forth in this Agreement shall relieve the Grantor from the performance of any term, covenant, condition or agreement on the Grantor's part to be performed or observed under or in respect of any of the Pledged Collateral or from any liability to any Person under or in respect of any of the Pledged Collateral or impose any obligation on the Administrative Agent or any other Finance Party to perform or observe any such term, covenant, condition or agreement on the Grantor's part to be so performed or observed or impose any liability on the Administrative Agent or any other Finance Party for any act or omission on the part of the Grantor relating thereto or for any breach of any representation or warranty on the part of the Grantor contained in this Agreement or any other Loan Document or under or in respect of the Pledged Collateral or made in connection herewith or therewith. The obligations of the Grantor contained in this Section 2 shall survive the termination of this Agreement and the discharge of the Grantor's other obligations hereunder and under the other Loan Documents.

3. Supplements; Further Assurances.

(a) The Grantor hereby authorizes the Administrative Agent to file, and if requested will deliver to the Administrative Agent, all financing statements and other documents and take such other actions as may from time to time be reasonably requested by the Administrative Agent in order to maintain a first perfected security interest in the Pledged Collateral owned by the Grantor. Any financing statement filed by the Administrative Agent may be filed in any filing office (including, without limitation, the United States Patent and Trademark Office, and appropriate state trademark offices) in any UCC jurisdiction, as the Administrative Agent may reasonably deem necessary or appropriate, wherever required or permitted by law in order to perfect and preserve the rights and interests granted to the Administrative Agent for the benefit of the Finance Parties hereunder. The Grantor also agrees to furnish any such information to the Administrative Agent promptly upon request. The Grantor also ratifies its authorization for the Administrative Agent to have filed in any UCC jurisdiction any initial financing statements or amendments thereto if filed prior to the date hereof.

(b) The Grantor will, if so reasonably requested by the Administrative Agent, furnish to the Administrative Agent, as often as the Administrative Agent reasonably requests, statements and schedules further identifying and describing the Pledged Collateral owned by the Grantor and such other reports and information in connection with its Pledged Collateral as the Administrative Agent may reasonably request, all in such detail as the Administrative Agent may specify. The Grantor also agrees to take any and all actions reasonably requested by the Administrative Agent to defend title to the Pledged Collateral against all persons and to defend the security interest of the Administrative Agent in its Pledged Collateral and the priority thereof against any Lien not expressly permitted hereunder.

4. Representations and Warranties of the Grantor. The Grantor hereby represents and warrants to the Finance Parties as follows:

(a) As of the Effective Date, the Grantor does not have any interest in, or title to, any Patent or Trademark, in each case, material to the Grantor's business, except as set forth in Schedules A and B hereto.

(b) This Agreement is effective to create a valid and continuing Lien and, upon filing of appropriate financing statements in the appropriate offices under the UCC and this Agreement with the United States Patent and Trademark Office, the Administrative Agent will have fully perfected security interests in favor of the Administrative Agent on the Grantor's Patents and Trademarks, having priority over all other Liens on the Pledged Collateral other than Permitted Liens and such perfected security interests are enforceable as such as against any and all creditors of and purchasers from the Grantor.

(c) Except (i) as set forth on Schedule C hereto, (ii) filings with the Patent and Trademark Office, under the UCC and under applicable foreign law, and (iii) those which have been made or obtained, no authorization, consent, approval, license, qualification or formal exemption from, nor any filing, declaration or registration with, any court (other than in connection with the exercise of judicial remedies), governmental agency or regulatory authority, or with any securities exchange or any other Person is required in connection with (1) the pledge by the Grantor of the Pledged Collateral pursuant to this Agreement, or the execution, delivery or performance by the Grantor of this Agreement, (2) the grant of a security interest (including the priority thereof when the appropriate filings have been made and accepted) in, the Pledged Collateral by the Grantor in the manner and for the purpose contemplated by this Agreement or (3) the exercise of the rights and remedies of the Administrative Agent created hereby.

(d) Except as set forth on Schedule D attached hereto, no material claim has been made and remains outstanding that the Grantor's use of the Pledged Collateral does or may violate the rights of any third person.

5. Covenants.

(a) The Grantor shall notify the Administrative Agent immediately if it knows or has reason to know that any application or registration relating to any Patent or Trademark (now or hereafter existing) material to the conduct of the business of the Borrower and its Subsidiaries taken as a whole may become abandoned or dedicated, or of any adverse determination or development (including the institution of, or any such determination or development in, any proceeding in the United States Patent and Trademark Office or any court) regarding the Grantor's ownership of any Patent or Trademark, its right to register the same, or to keep and maintain the same.

(b) Upon request of the Administrative Agent, the Grantor shall execute and deliver any and all security agreements as the Administrative Agent may request to evidence the Administrative

Agent's first priority security interest on any Patent or Trademark of the Grantor material to the business of the Borrower and its Subsidiaries taken as a whole relating thereto or represented thereby.

(c) The Grantor shall take all actions necessary or requested by the Administrative Agent to maintain and pursue each application, to obtain the relevant registration and to maintain the registration of each of its Patents and Trademarks (now or hereafter existing) material to the conduct of the business of the Borrower and its Subsidiaries taken as a whole, including the filing of applications for renewal, affidavits of use, affidavits of noncontestability and opposition and interference and cancellation proceedings, unless the Grantor shall reasonably determine that such Patent or Trademark is not material to the conduct of the business of the Borrower and its Subsidiaries taken as whole.

(d) The Grantor shall, unless it shall reasonably determine that such Patent or Trademark is in no way material to the conduct of the business of the Borrower and its Subsidiaries taken as a whole or the Grantor shall reasonably determine that such action is not appropriate, promptly sue for infringement, misappropriation or dilution and to recover any and all damages for such infringement, misappropriation or dilution, and shall take such other actions as the Administrative Agent shall deem appropriate under the circumstances to protect such Patent or Trademark.

6. Events of Default. The occurrence of any "Event of Default" under, and as defined in, the Credit Agreement shall constitute an Event of Default hereunder.

7. Remedies upon an Event of Default.

(a) Upon the occurrence and during the continuance of an Event of Default, the Administrative Agent may exercise any or all of the following rights and remedies:

(1) those rights and remedies provided in this Agreement, the Credit Agreement, or any other Loan Document; *provided that*, this Section 7(a)(1) shall not be understood to limit any rights or remedies available to the Administrative Agent and the Finance Parties prior to an Event of Default;

(2) those rights and remedies available to a secured party under the UCC (whether or not the UCC applies to the affected Pledged Collateral) or under any other applicable law (including, without limitation, any law governing the exercise of a bank's right of setoff or bankers' lien) when a debtor is in default under a security agreement; and

(3) (i) any and all rights on a nonexclusive basis throughout the world irrevocably and perpetually as if it were the beneficial and legal owner or licensee, as the case may be, of the Pledged Collateral, including, without limitation, perfecting assignment of any and all contractual rights and powers with respect to the Pledged Collateral to the extent permitted by such Pledged Collateral and (ii) sell or assign or grant a license to use, or cause to be sold or assigned or a license granted to use any or all of the Pledged Collateral (in the case of Trademarks, along with the goodwill associated therewith, and in the case of Trademark licenses, subject to the quality control provisions in the original license) or any part thereof, in each case, free of all rights and claims of the Grantor therein and thereto. In accordance with such rights, the Administrative Agent shall have (A) the right to cause any or all of the Pledged Collateral to be transferred of record into the name of the Administrative Agent or its nominee and (B) the right to impose (i) such limitations and restrictions on the sale or assignment of the Pledged Collateral as the Finance Parties may deem to be necessary or appropriate to comply with any law, rule or regulation (federal, state or local) having applicability to the sale or assignment, and

(ii) any necessary or appropriate requirements for any required governmental approvals or consents.

(4) if at any time the Administrative Agent has the right to dispose of any of the Pledged Collateral which is subject to a Patent or Trademark which any of the Grantor own or control through a license or otherwise, the Grantor grants to the Administrative Agent, for the benefit of the Finance Parties, a royalty free license (to the extent such rights are assignable) to use any such Patent, or Trademark, in addition to the grant of any security interest granted to the Administrative Agent, for the benefit of the Finance Parties, in such Patent or Trademark to the extent necessary to dispose of any such Pledged Collateral.

(b) The Administrative Agent, on behalf of the Finance Parties, may comply with any applicable state or federal law requirements in connection with a disposition of the Pledged Collateral and compliance will not be considered to adversely affect the commercial reasonableness of any sale of the Pledged Collateral.

(c) Until the Administrative Agent is able to effect a sale, lease, or other disposition of Pledged Collateral, the Administrative Agent shall have the right to hold or use Pledged Collateral, or any part thereof, to the extent that it deems appropriate for the purpose of preserving Pledged Collateral or its value or for any other purpose deemed appropriate by the Administrative Agent. The Administrative Agent may, if it so elects, seek the appointment of a receiver or keeper to take possession of Pledged Collateral and to enforce any of the Administrative Agent's remedies (for the benefit of the Administrative Agent and Finance Parties), with respect to such appointment without prior notice or hearing as to such appointment.

(d) If, after the Credit Agreement has terminated by its terms and all of the Obligations have been paid in full, there remain Swap Obligations outstanding, the Required Secured Parties may exercise the remedies provided in this Section 7 upon the occurrence of any event which would allow or require the termination or acceleration of any Swap Obligations pursuant to the terms of the Swap Agreement. For purposes of this Section 7(d) and Section 8(b), "Required Secured Parties" means (1) prior to an acceleration of the Obligations under the Credit Agreement, the Required Lenders, (2) after an acceleration of the Obligations under the Credit Agreement but prior to the date upon which the Obligations have been paid in full and the Credit Agreement has been terminated, Lenders holding in the aggregate at least a majority of the aggregate Revolving Credit Exposure of all Lenders, and (3) after the Credit Agreement has been terminated and all Obligations have been paid in full (whether or not the Obligations under the Credit Agreement were ever accelerated), Lenders holding in the aggregate at least a majority of the aggregate net early termination payments and all other amounts then due and unpaid from the Grantor to the Finance Parties under any Swap Agreement, as determined by the Administrative Agent in its reasonable discretion.

(e) Notwithstanding the foregoing, neither the Administrative Agent nor the Finance Parties shall be required to (i) make any demand upon, or pursue or exhaust any of their rights or remedies against, the Grantor, any other obligor, guarantor, pledgor or any other Person with respect to the payment of the Secured Obligations or to pursue or exhaust any of their rights or remedies with respect to any Pledged Collateral therefor or any direct or indirect guarantee thereof, (ii) marshal the Pledged Collateral or any guarantee of the Secured Obligations or to resort to the Pledged Collateral or any such guarantee in any particular order, or (iii) effect a public sale of any Pledged Collateral.

8. Transfers and Other Liens.

(a) The Grantor will not create, incur, or suffer to exist any Lien on the Pledged Collateral owned by the Grantor except (i) the security interest created by this Agreement, and (ii) other Permitted Liens.

(b) Except for dispositions specifically permitted by Section 6.05 of the Credit Agreement, the Grantor is not authorized to sell or otherwise dispose of the Pledged Collateral and notwithstanding any course of dealing between the Grantor and the Administrative Agent or other conduct of the Administrative Agent, no authorization to sell or otherwise dispose of the Pledged Collateral (except for dispositions specifically permitted pursuant to Section 6.05 of the Credit Agreement) shall be binding upon the Administrative Agent or the Finance Parties unless such authorization is in writing and signed by the Administrative Agent with the consent or at the direction of the Required Secured Parties (as defined in Section 7(d)).

9. Application of Pledged Collateral Proceeds. In the case of any sale or other disposition of Pledged Collateral by the Administrative Agent in the exercise of its remedies provided in this Agreement or in any other Loan Document, the proceeds of such sale or other disposition shall be applied in accordance with Section 2.19 of the Credit Agreement. In the event that the proceeds from any sale or other disposition of Pledged Collateral are insufficient to pay all Secured Obligations in full, the Grantor shall remain liable for any deficiency, including any attorneys' fees and other expenses incurred by the Administrative Agent or any Finance Party to collect such deficiency.

10. Expenses. The Grantor shall reimburse the Administrative Agent for any and all expenses in connection with the preparation, execution, delivery, administration, collection and enforcement of this Agreement and in the administration, collection, preservation or sale of the Pledged Collateral as and to the extent the Borrower would be required to do so by Section 9.03(a) of the Credit Agreement. Any and all costs and expenses incurred by the Grantor in the performance of actions required pursuant to the terms hereof shall be borne solely by the Grantor.

11. No Waiver; Amendments; Cumulative Remedies. No delay or omission of the Administrative Agent or any Finance Party to exercise any right or remedy granted under this Agreement shall impair such right or remedy or be construed to be a waiver of any Default or an acquiescence therein, and any single or partial exercise of any such right or remedy shall not preclude any other or further exercise thereof or the exercise of any other right or remedy. No waiver, amendment or other variation of the terms, conditions or provisions of this Agreement whatsoever shall be valid unless in writing signed by the Administrative Agent with the concurrence or at the direction of the Finance Parties required under Section 9.02 of the Credit Agreement and then only to the extent in such writing specifically set forth. All rights and remedies contained in this Agreement or by law afforded shall be cumulative and all shall be available to the Administrative Agent and the Finance Parties until the Secured Obligations have been paid in full.

12. The Administrative Agent Appointed Attorney-in-Fact.

(a) The Grantor irrevocably authorizes the Administrative Agent at any time and from time to time in the sole discretion of the Administrative Agent and appoints the Administrative Agent as its attorney in fact (i) to execute on behalf of the Grantor as debtor and to file financing statements necessary or desirable in the Administrative Agent's sole discretion to perfect and to maintain the perfection and priority of the Administrative Agent's security interest in the Pledged Collateral, (ii) to file a carbon, photographic or other reproduction of this Agreement or any financing statement with respect to the Pledged Collateral as a financing statement and to file any other financing statement or amendment of a financing statement (which does not add new collateral or add a debtor) in such offices as the Administrative Agent in its sole discretion deems necessary or desirable to perfect and to maintain the

perfection and priority of the Administrative Agent's security interest in the Pledged Collateral, (iii) to discharge past due taxes, assessments, charges, fees or Liens on the Pledged Collateral (except for such Liens as are specifically permitted hereunder), (iv) to apply the proceeds of any Pledged Collateral received by the Administrative Agent to the Secured Obligations as provided in Section 9, (v) to endorse and collect any cash proceeds of the Pledged Collateral, (vi) to change the address for delivery of mail addressed to the Grantor to such address as the Administrative Agent may designate and to receive, open and dispose of all mail addressed to the Grantor, and (vii) to do all other acts and things necessary to carry out this Agreement; and the Grantor agrees to reimburse the Administrative Agent as and to the extent the Borrower would be required to do so pursuant to Section 9.03(a) of the Credit Agreement for any payment made or any expense incurred by the Administrative Agent in connection with any of the foregoing; *provided that*, this authorization shall not relieve the Grantor of any of its obligations under this Agreement or under the Credit Agreement.

(b) All acts of said attorney or designee are hereby ratified and approved. The powers conferred on the Administrative Agent, for the benefit of the Administrative Agent and Finance Parties, under this Section 12(a) are solely to protect the Administrative Agent's interests in the Pledged Collateral and shall not impose any duty upon the Administrative Agent or any Finance Party to exercise any such powers. The Administrative Agent agrees that, except for the powers granted in Sections 12(a)(i), (ii), (iv) and Section 12(a)(vii), it shall not exercise any power or authority granted to it unless an Event of Default has occurred and is continuing.

13. Indemnity. The Grantor hereby agrees to indemnify the Administrative Agent and the Finance Parties and each of their respective Related Parties as and to the extent the Borrower would be required to do so by Section 9.03(b) of the Credit Agreement.

14. Litigation.

(a) The Grantor shall have the right to commence and prosecute in its own name, as real party in interest, for its own benefit and at its own expense, such applications for protection of the Pledged Collateral, suits, proceedings or other actions for infringement, counterfeiting, unfair competition, dilution or other damage as are in its reasonable business judgment necessary to protect the Pledged Collateral. The Administrative Agent shall provide all reasonable and necessary cooperation in connection with any such suit, proceeding or action, including, without limitation, joining as a necessary party.

(b) Upon the occurrence and during the continuation of an Event of Default, such Event of Default not having been previously waived, remedied or cured, the Administrative Agent shall have the right but shall in no way be obligated to file applications for protection of the Pledged Collateral and/or bring suit in the name of the Grantor, the Administrative Agent or the Finance Parties to enforce the Pledged Collateral and any license thereunder; in the event of such suit, the Grantor shall, at the request of the Administrative Agent, do any and all lawful acts and execute any and all documents required by the Administrative Agent in aid of such enforcement and the Grantor shall promptly, upon demand, reimburse and indemnify the Administrative Agent, as the case may be, for all costs and expenses incurred by the Administrative Agent in the exercise of its rights under this Section 14.

15. Release.

(a) At such time as the Commitments have expired or been terminated and the principal of and interest on each Loan shall have been paid in full, all Letters of Credit shall have expired or terminated (or cash collateralized to the satisfaction of the Issuing Bank) and all LC Disbursements shall have been reimbursed and all other Secured Obligations (other than contingent indemnification and

contingent expense reimbursement obligations) shall have been paid in full, the Pledged Collateral shall be released automatically from the Liens and security interests created hereby, and this Agreement and all obligations (other than those expressly stated to survive such termination) of the Administrative Agent and the Grantor hereunder shall terminate, all without delivery of any instrument or performance of any act by any party, and all rights to the Pledged Collateral shall revert to the Grantor. At the request and sole expense of the Grantor following any such termination, the Administrative Agent shall deliver to the Grantor any Pledged Collateral held by the Administrative Agent hereunder, and execute and deliver to the Grantor such documents as the Grantor shall reasonably request to evidence such termination.

(b) If any of the Pledged Collateral shall be sold, transferred or otherwise disposed of by the Grantor in a transaction permitted by the Credit Agreement, then (i) the Liens and security interests created hereby on Pledged Collateral shall automatically be released and (ii) the Administrative Agent, at the request and sole expense of the Grantor, shall promptly execute and deliver to the Grantor all releases or other documents reasonably necessary or desirable to evidence such release of the Liens created hereby on such Pledged Collateral. At the request and sole expense of the Borrower, the Grantor shall be released automatically from its obligations hereunder in the event that all the Equity Interests of the Grantor shall be sold, transferred or otherwise disposed of in a transaction permitted by the Credit Agreement.

16. Reinstatement. This Agreement shall remain in full force and effect and continue to be effective should any petition be filed by or against the Grantor for liquidation or reorganization, should the Grantor become insolvent or make an assignment for the benefit of any creditor or creditors or should a receiver or trustee be appointed for all or any significant part of the Grantor's assets, and shall continue to be effective or be reinstated, as the case may be, if at any time payment and performance of the Secured Obligations, or any part thereof, is, pursuant to applicable law, rescinded or reduced in amount, or must otherwise be restored or returned by any obligee of the Secured Obligations, whether as a "voidable preference," "fraudulent conveyance," or otherwise, all as though such payment or performance had not been made. In the event that any payment, or any part thereof, is rescinded, reduced, restored or returned, the Secured Obligations shall be reinstated and deemed reduced only by such amount paid and not so rescinded, reduced, restored or returned.

17. Notices.

(a) Sending Notices. Any notice required or permitted to be given under this Agreement shall be sent by United States mail, telecopier, personal delivery or nationally established overnight courier service, and shall be deemed received (1) when received, if sent by hand or overnight courier service, or mailed by certified or registered mail notices or (2) when sent, if sent by telecopier (except that, if not given during normal business hours for the recipient, shall be deemed to have been given at the opening of business on the next Business Day for the recipient), in each case addressed to the Grantor at the notice address set forth on Schedule E, and to the Administrative Agent and the Finance Parties at the addresses set forth in accordance with Section 9.01 of the Credit Agreement.

(b) Change in Address for Notices. The Grantor, the Administrative Agent and the Finance Parties may change the address for service of notice upon it by a notice in writing to the other parties.

18. Benefit of Agreement: Assignment. The terms and provisions of this Agreement shall be binding upon and inure to the benefit of the Grantor, the Administrative Agent and the Finance Parties and their respective successors and assigns (including all persons who become bound as a debtor to this Agreement), except that the Grantor shall not have the right to assign its rights or delegate its obligations under this Agreement or any interest herein, without the prior written consent of the Administrative

Agent. No sales of participations, assignments, transfers, or other dispositions of any agreement governing the Secured Obligations or any portion thereof or interest therein shall in any manner impair the Lien granted to the Administrative Agent, for the benefit of the Administrative Agent and the Finance Parties, hereunder.

19. CHOICE OF LAW. THIS AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE INTERNAL LAWS (AND NOT THE LAW OF CONFLICTS) OF THE STATE OF NEW YORK, BUT GIVING EFFECT TO FEDERAL LAWS APPLICABLE TO NATIONAL BANKS.

20. CONSENT TO JURISDICTION. THE GRANTOR HEREBY IRREVOCABLY SUBMITS TO THE NON-EXCLUSIVE JURISDICTION OF ANY U.S. FEDERAL OR NEW YORK STATE COURT SITTING IN NEW YORK, NEW YORK IN ANY ACTION OR PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT OR ANY OTHER LOAN DOCUMENT AND THE GRANTOR HEREBY IRREVOCABLY AGREES THAT ALL CLAIMS IN RESPECT OF SUCH ACTION OR PROCEEDING MAY BE HEARD AND DETERMINED IN ANY SUCH COURT AND IRREVOCABLY WAIVES ANY OBJECTION IT MAY NOW OR HEREAFTER HAVE AS TO THE VENUE OF ANY SUCH SUIT, ACTION OR PROCEEDING BROUGHT IN SUCH A COURT OR THAT SUCH COURT IS AN INCONVENIENT FORUM. NOTHING HEREIN SHALL LIMIT THE RIGHT OF THE ADMINISTRATIVE AGENT OR ANY FINANCE PARTY TO BRING PROCEEDINGS AGAINST THE GRANTOR IN THE COURTS OF ANY OTHER JURISDICTION. ANY JUDICIAL PROCEEDING BY THE GRANTOR AGAINST THE ADMINISTRATIVE AGENT OR ANY FINANCE PARTY OR ANY AFFILIATE OF THE AGENT OR ANY LENDER INVOLVING, DIRECTLY OR INDIRECTLY, ANY MATTER IN ANY WAY ARISING OUT OF, RELATED TO, OR CONNECTED WITH THIS AGREEMENT OR ANY OTHER LOAN DOCUMENT SHALL BE BROUGHT ONLY IN A COURT IN NEW YORK, NEW YORK.

21. WAIVER OF JURY TRIAL. THE GRANTOR, THE ADMINISTRATIVE AGENT AND EACH FINANCE PARTY HEREBY WAIVE TRIAL BY JURY IN ANY JUDICIAL PROCEEDING INVOLVING, DIRECTLY OR INDIRECTLY, ANY MATTER (WHETHER SOUNDING IN TORT, CONTRACT OR OTHERWISE) IN ANY WAY ARISING OUT OF, RELATED TO, OR CONNECTED WITH THIS AGREEMENT OR ANY OTHER LOAN DOCUMENT OR THE RELATIONSHIP ESTABLISHED THEREUNDER.

22. Limitation by Law; Severability of Provisions. All rights, remedies and powers provided in this Agreement may be exercised only to the extent that the exercise thereof does not violate any applicable provision of law, and all the provisions of this Agreement are intended to be subject to all applicable mandatory provisions of law that may be controlling and to be limited to the extent necessary so that they shall not render this Agreement invalid, unenforceable or not entitled to be recorded or registered, in whole or in part. Any provision in any this Agreement that is held to be inoperative, unenforceable, or invalid in any jurisdiction shall, as to that jurisdiction, be inoperative, unenforceable, or invalid without affecting the remaining provisions in that jurisdiction or the operation, enforceability, or validity of that provision in any other jurisdiction, and to this end the provisions of this Agreement are declared to be severable.

23. Execution in Counterparts. This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one agreement, and any of the parties hereto may execute this Agreement by signing any such counterpart. Delivery of an executed counterpart of a signature page of this Agreement by facsimile or by sending a scanned copy by electronic mail shall be effective as delivery of a manually executed counterpart of this Agreement.

24. Headings. The title of and section headings in this Agreement are for convenience of reference only, and shall not govern the interpretation of any of the terms and provisions of this Agreement.


[Signature Page Follows]

42

IN WITNESS WHEREOF, the parties hereto have caused this Patent and Trademark Security Agreement to be duly executed as of the date first above written.

GRANTOR:

BIOVAIL LABORATORIES INTERNATIONAL
SRL

By: 

Name: _____

Title: _____

ANDREW V. THORNHILL
ATTORNEY-AT-LAW

ACKNOWLEDGMENT OF SIGNATURE


STATE OF _____

SS

COUNTY OF _____

I, _____, a Notary Public in and for said State, DO HEREBY
CERTIFY THAT _____ the _____ of BIOVAIL
LABORATORIES INTERNATIONAL SRL, proven to me to be the same person whose name
is subscribed to the foregoing instrument as such officer, appeared before me this day in person
and acknowledged that he signed and delivered said instrument as his own free and voluntary
act and as the free and voluntary act of said company.

IN WITNESS WHEREOF, I have hereunto set my hand and official seal this _____ day of
June, 2009.


Notary Public

SHONTELLE M. WURRELL
ATTORNEY-AT-LAW

My Commission expires: _____

[Signature page in US Patent and Trademark Security Agreement]

ADMINISTRATIVE AGENT:

JPMORGAN CHASE BANK, N.A., TORONTO
BRANCH

By: Robert S. Sheppard

Name: Robert S. Sheppard

Title: Vice President

ACKNOWLEDGMENT OF SIGNATURES


STATE OF Illinois }
COUNTY OF Cook } SS

I, Mary J. DaSilva, a Notary Public in and for said State, DO HEREBY
CERTIFY THAT Robert Sheppard, the V.P. of JPMORGAN CHASE BANK, N.A.,
TORONTO BRANCH, proven to me to be the same person whose name is subscribed to the foregoing
instrument as such officer, appeared before me this day in person and acknowledged that he signed and
delivered said instrument as his own free and voluntary act and as the free and voluntary act of said
company.

IN WITNESS WHEREOF, I have hereunto set my hand and official seal this 29th day of June,
2009.

Mary J. DaSilva
Notary Public

My Commission expires: March 29, 2010



[Signature page to US Patent and Trademark Security Agreement]

[The following have become parties to this Agreement as of the date set forth next to their respective signatures:]

ADDITIONAL GRANTORS

[NAME OF GRANTOR]

Dated: _____

By: _____

Name:

Title:

PATENTS

(including exclusive and nonexclusive licenses)

See attached.

Error! Unknown document property name.

BIOVAIL MATERIAL PATENT PORTFOLIO

Biovail Case Reference	Title	Country /Region	Filing Date	Filing Number	Grant Date	Grant Number	Expiration Date	Current Status	Registered Owners	Notes
------------------------	-------	-----------------	-------------	---------------	------------	--------------	-----------------	----------------	-------------------	-------

P003 family relates to WELLBUTRIN XL in the US and Canada and WELLBUTRIN XR in ROW. With the exception of the US (P003-US-CNT) and Canada (P003-CA-PCT), the entire P003 family has been licensed to GSK.

P003-AE-PCT	MODIFIED RELEASE TABLET OF BUPROPION HYDROCHLORIDE	United Arab Emirates	08 Aug 2003	650/2005			08 Aug 2023	Pending	Biovail Laboratories International SRL	
P003-AP-AFT	MODIFIED RELEASE TABLET OF BUPROPION HYDROCHLORIDE	ARIPO	08 Aug 2003	AP/P/2005/003463	31 Oct 2008	AP 1899	08 Aug 2023	Granted	Biovail Laboratories International SRL	
P003-AU-PCT	MODIFIED RELEASE TABLET OF BUPROPION HYDROCHLORIDE	Australia	08 Aug 2003	2003264002			08 Aug 2023	Pending	Biovail Laboratories International SRL	
P003-BA-PCT	MODIFIED RELEASE TABLET OF BUPROPION HYDROCHLORIDE	Bosnia-Herzegovina	08 Aug 2003	BAP 062336A			08 Aug 2023	Pending	Biovail Laboratories International SRL	
P003-BB-PCT	MODIFIED RELEASE TABLET OF BUPROPION HYDROCHLORIDE	Barbados	08 Aug 2003	2001/1186			08 Aug 2023	Pending	Biovail Laboratories International SRL	

PATENT

BIOVAIL MATERIAL PATENT PORTFOLIO										
Biovail Case Reference	Title	Country /Region	Filing Date	Filing Number	Grant Date	Grant Number	Expiration Date	Current Status	Registered Owners	Notes
P003-BD-NP	MODIFIED RELEASE TABLET OF BUPROPION HYDROCHLORIDE	Bangladesh	09 Feb 2006	21/2006	24 Oct 2007	1004635	09 Feb 2022	Granted	Biovail Laboratories International SRL	
P003-BO-NP	MODIFIED RELEASE TABLET OF BUPROPION HYDROCHLORIDE	Bolivia	08 Nov 2005	SP-250295			08 Nov 2025	Pending	Biovail Laboratories International SRL	
P003-BR-PCT	MODIFIED RELEASE TABLET OF BUPROPION HYDROCHLORIDE	Brazil	08 Aug 2003	PI0318456-0			08 Aug 2023	Pending	Biovail Laboratories International SRL	
P003-CA-PCT	MODIFIED RELEASE TABLET OF BUPROPION HYDROCHLORIDE	Canada	08 Aug 2003	2,524,300	28 Oct 2008	2,524,300	08 Aug 2023	Granted	Biovail Laboratories International SRL	
P003-CL-REV	MODIFIED RELEASE TABLET OF BUPROPION HYDROCHLORIDE	Chile	03 Oct 2005	2581-2005			03 Oct 2025	Pending	Biovail Laboratories International SRL	
P003-CN-PCT	MODIFIED RELEASE TABLET OF BUPROPION HYDROCHLORIDE	China	08 Aug 2003	03826750.0			08 Aug 2023	Pending	Biovail Laboratories International SRL	

PATENT

BIOVAIL MATERIAL PATENT PORTFOLIO										
Biovail Case Reference	Title	Country /Region	Filing Date	Filing Number	Grant Date	Grant Number	Expiration Date	Current Status	Registered Owners	Notes
P003-CO-PCT	MODIFIED RELEASE TABLET OF BUPROPION HYDROCHLORIDE	Colombia	08 Aug 2003	05122667			08 Aug 2023	Pending	Biovail Laboratories International SRL	
P003-CR-PCT	MODIFIED RELEASE TABLET OF BUPROPION HYDROCHLORIDE	Costa Rica	08 Aug 2003	8056			08 Aug 2023	Pending	Biovail Laboratories International SRL	
P003-DZ-PCT	MODIFIED RELEASE TABLET OF BUPROPION HYDROCHLORIDE	Algeria	08 Aug 2003	050516			08 Aug 2023	Pending	Biovail Laboratories International SRL	
P003-EA-EAT	MODIFIED RELEASE TABLET OF BUPROPION HYDROCHLORIDE	Eurasian Procedure	08 Aug 2003	200600206			08 Aug 2023	Pending	Biovail Laboratories International SRL	
P003-EC-PCT	MODIFIED RELEASE TABLET OF BUPROPION HYDROCHLORIDE	Ecuador	08 Aug 2003	SP-05-6216			08 Aug 2023	Pending	Biovail Laboratories International SRL	
P003-EG-PCT	MODIFIED RELEASE TABLET OF BUPROPION HYDROCHLORIDE	Egypt	08 Jan 2003	PCT/NA2006/00015			08 Jan 2026	Pending	Biovail Laboratories International SRL	

PATENT

BIOVAIL MATERIAL PATENT PORTFOLIO										
Biovail Case Reference	Title	Country /Region	Filing Date	Filing Number	Grant Date	Grant Number	Expiration Date	Current Status	Registered Owners	Notes
P003-EP-EPT	MODIFIED RELEASE TABLET OF BUPROPION HYDROCHLORIDE	European Procedure (Patents)	08 Aug 2003	03818223.4			08 Aug 2023	Pending	Biovail Laboratories International SRL	
P003-GE-PCT	MODIFIED RELEASE TABLET OF BUPROPION HYDROCHLORIDE	Georgia	08 Aug 2003	AP2003009205	07 Nov 2006	P4128	08 Aug 2023	Granted	Biovail Laboratories International SRL	
P003-GH-AFT	MODIFIED RELEASE TABLET OF BUPROPION HYDROCHLORIDE	Ghana			31 Oct 2008	AP 1899	08 Aug 2023	Granted	Biovail Laboratories International SRL	
P003-GM-AFT	MODIFIED RELEASE TABLET OF BUPROPION HYDROCHLORIDE	Gambia			31 Oct 2008	AP1899	08 Aug 2023	Granted	Biovail Laboratories International SRL	
P003-GT-NP	MODIFIED RELEASE TABLET OF BUPROPION HYDROCHLORIDE	Guatemala	23 Nov 2005	PI-2005-0342			23 Nov 2025	Pending	Biovail Laboratories International SRL	
P003-GZ-NP	MODIFIED RELEASE TABLET OF BUPROPION HYDROCHLORIDE	Gaza Strip	07 Dec 2005	79	29 Apr 2007	79	07 Dec 2021	Granted	Biovail Laboratories International SRL	

PATENT

Error! Unknown document property name.

BIOVAIL MATERIAL PATENT PORTFOLIO

Biovail Case Reference	Title	Country /Region	Filing Date	Filing Number	Grant Date	Grant Number	Expiration Date	Current Status	Registered Owners	Notes
P003-HK-FPR	MODIFIED RELEASE TABLET OF BUPROPION HYDROCHLORIDE	Hong Kong	10 May 2006	06103123.8			10 May 2026	Pending	Biovail Laboratories International SRL	
P003-HR-PCT	MODIFIED RELEASE TABLET OF BUPROPION HYDROCHLORIDE	Croatia	08 Aug 2003	P20050625			08 Aug 2023	Pending	Biovail Laboratories International SRL	
P003-ID-PCT	MODIFIED RELEASE TABLET OF BUPROPION HYDROCHLORIDE	Indonesia	08 Aug 2003	WO200600107			08 Aug 2023	Pending	Biovail Laboratories International SRL	
P003-IL-PCT	MODIFIED RELEASE TABLET OF BUPROPION HYDROCHLORIDE	Israel	08 Aug 2003	171870			08 Aug 2023	Pending	Biovail Laboratories International SRL	
P003-IN-PCT	MODIFIED RELEASE TABLET OF BUPROPION HYDROCHLORIDE	India	08 Aug 2003	6091/DELNP/2005			08 Aug 2023	Pending	Biovail Laboratories International SRL	
P003-IQ-NP	MODIFIED RELEASE TABLET OF BUPROPION HYDROCHLORIDE	Iraq	19 Dec 2005	201/2005			08 Aug 2023	Pending	Biovail Laboratories International SRL	

PATENT

BIOVAIL MATERIAL PATENT PORTFOLIO										
Biovail Case Reference	Title	Country /Region	Filing Date	Filing Number	Grant Date	Grant Number	Expiration Date	Current Status	Registered Owners	Notes
P003-IS-PCT	MODIFIED RELEASE TABLET OF BUPROPION HYDROCHLORIDE	Iceland	08 Aug 2003	7930			08 Aug 2023	Pending	Biovail Laboratories International SRL	
P003-JM-NP	MODIFIED RELEASE TABLET OF BUPROPION HYDROCHLORIDE	Jamaica	03 Nov 2005	18/1/4399			08 Aug 2023	Pending	Biovail Laboratories International SRL	
P003-JP-PCT	MODIFIED RELEASE TABLET OF BUPROPION HYDROCHLORIDE	Japan	08 Aug 2003	2005-507893			08 Aug 2023	Pending	Biovail Laboratories International SRL	
P003-KE-AFT	MODIFIED RELEASE TABLET OF BUPROPION HYDROCHLORIDE	Kenya			31 Oct 2008	AP1899	08 Aug 2023	Granted	Biovail Laboratories International SRL	
P003-KP-PCT	MODIFIED RELEASE TABLET OF BUPROPION HYDROCHLORIDE	North Korea / Demo. People's Republic of Korea	08 Aug 2003	05-1665	20 Mar 2007	45061	08 Aug 2023	Granted	Biovail Laboratories International SRL	
P003-KR-PCT	MODIFIED RELEASE TABLET OF BUPROPION HYDROCHLORIDE	South Korea / Republic of Korea	08 Aug 2003	10-2006-7002659			08 Aug 2023	Pending	Biovail Laboratories International SRL	

PATENT

BIOVAIL MATERIAL PATENT PORTFOLIO										
Biovail Case Reference	Title	Country /Region	Filing Date	Filing Number	Grant Date	Grant Number	Expiration Date	Current Status	Registered Owners	Notes
P003-KS-NP	MODIFIED RELEASE TABLET OF BUPROPION HYDROCHLORIDE	Kosovo	08 Aug 2003	P-035			08 Aug 2023	Pending	Biovail Laboratories International SRL	
P003-KW-NP	MODIFIED RELEASE TABLET OF BUPROPION HYDROCHLORIDE	Kuwait	20 Dec 2005	152/2005			20 Dec 2025	Pending	Biovail Laboratories International SRL	
P003-LK-PCT	MODIFIED RELEASE TABLET OF BUPROPION HYDROCHLORIDE	Sri Lanka	08 Aug 2003	13981			08 Aug 2023	Pending	Biovail Laboratories International SRL	
P003-LS-AFT	MODIFIED RELEASE TABLET OF BUPROPION HYDROCHLORIDE	Lesotho			31 Oct 2008	AP1899	08 Aug 2023	Granted	Biovail Laboratories International SRL	
P003-LY-NP	MODIFIED RELEASE TABLET OF BUPROPION HYDROCHLORIDE	Libyan Arab Jamahiriya	12 Mar 2006	3360/2006			12 Mar 2021	Pending	Biovail Laboratories International SRL	
P003-MA-PCT	MODIFIED RELEASE TABLET OF BUPROPION HYDROCHLORIDE	Morocco	08 Aug 2003	PV28772			08 Aug 2023	Pending	Biovail Laboratories International SRL	

PATENT

BIOVAIL MATERIAL PATENT PORTFOLIO

Biovail Case Reference	Title	Country /Region	Filing Date	Filing Number	Grant Date	Grant Number	Expiration Date	Current Status	Registered Owners	Notes
P003-ME-PCT	MODIFIED RELEASE TABLET OF BUPROPION HYDROCHLORIDE	Montenegro	08 Aug 2003	P-36/08			08 Aug 2023	Pending	Biovail Laboratories International SRL	
P003-MG-PCT	MODIFIED RELEASE TABLET OF BUPROPION HYDROCHLORIDE	Madagascar	08 Aug 2003	2005/041	29 Jun 2007	00348	08 Aug 2023	Granted	Biovail Laboratories International SRL	
P003-MO-FPR	MODIFIED RELEASE TABLET OF BUPROPION HYDROCHLORIDE	Macao	08 Sep 2003	J/000084(617)			08 Aug 2023	Pending	Biovail Laboratories International SRL	
P003-MW-AFT	MODIFIED RELEASE TABLET OF BUPROPION HYDROCHLORIDE	Malawi			31 Oct 2008	AP1899	08 Aug 2023	Granted	Biovail Laboratories International SRL	
P003-MX-PCT	MODIFIED RELEASE TABLET OF BUPROPION HYDROCHLORIDE	Mexico	08 Aug 2003	PA/a/2005/012637			08 Aug 2023	Pending	Biovail Laboratories International SRL	
P003-MY-NP	MODIFIED RELEASE TABLET OF BUPROPION HYDROCHLORIDE	Malaysia	12 Jan 2006	PI 20060143			12 Jan 2026	Pending	Biovail Laboratories International SRL	

PATENT

Error! Unknown document property name.

BIOVAIL MATERIAL PATENT PORTFOLIO										
Biovail Case Reference	Title	Country /Region	Filing Date	Filing Number	Grant Date	Grant Number	Expiration Date	Current Status	Registered Owners	Notes
P003-MZ-AFT	MODIFIED RELEASE TABLET OF BUPROPION HYDROCHLORIDE	Mozambique			31 Oct 2008	AP1899	08 Aug 2023	Granted	Biovail Laboratories International SRL	
P003-NI-PCT	MODIFIED RELEASE TABLET OF BUPROPION HYDROCHLORIDE	Nicaragua	08 Aug 2003	2005/0206			08 Aug 2023	Pending	Biovail Laboratories International SRL	
P003-NO-PCT	MODIFIED RELEASE TABLET OF BUPROPION HYDROCHLORIDE	Norway	08 Aug 2003	20053245			08 Aug 2023	Pending	Biovail Laboratories International SRL	
P003-NP-NP	MODIFIED RELEASE TABLET OF BUPROPION HYDROCHLORIDE	Nepal	06 Feb 2006	5181			08 Aug 2023	Pending	Biovail Laboratories International SRL	
P003-NZ-PCT	MODIFIED RELEASE TABLET OF BUPROPION HYDROCHLORIDE	New Zealand	08 Aug 2003	544281	13 Nov 2008	544281	08 Aug 2023	Granted	Biovail Laboratories International SRL	
P003-OA-PCT	MODIFIED RELEASE TABLET OF BUPROPION HYDROCHLORIDE	A.I.P.O.	08 Aug 2003	1200600041			08 Aug 2023	Pending	Biovail Laboratories International SRL	

PATENT

BIOVAIL MATERIAL PATENT PORTFOLIO										
Biovail Case Reference	Title	Country /Region	Filing Date	Filing Number	Grant Date	Grant Number	Expiration Date	Current Status	Registered Owners	Notes
P003-OM-PCT	MODIFIED RELEASE TABLET OF BUPROPION HYDROCHLORIDE	Oman	08 Aug 2003	PCT/US2003/024700			08 Aug 2023	Pending	Biovail Laboratories International SRL	
P003-PA-NP	MODIFIED RELEASE TABLET OF BUPROPION HYDROCHLORIDE	Panama	02 Dec 2005	86544			02 Dec 2025	Pending	Biovail Laboratories International SRL	
P003-PH-PCT	MODIFIED RELEASE TABLET OF BUPROPION HYDROCHLORIDE	Philippines	08 Aug 2003	1-2006-500290			08 Aug 2023	Pending	Biovail Laboratories International SRL	
P003-PL-PCT	MODIFIED RELEASE TABLET OF BUPROPION HYDROCHLORIDE	Poland	08 Aug 2003	P-378539	18 Jun 2007	PAT-196544	08 Aug 2023	Granted	Biovail Laboratories International SRL	
P003-QA-CN	MODIFIED RELEASE TABLET OF BUPROPION HYDROCHLORIDE	Qatar		Cationary Notice				Pending	Biovail Laboratories International SRL	
P003-SA-NP	MODIFIED RELEASE TABLET OF BUPROPION HYDROCHLORIDE	Saudi Arabia	17 Jan 2006	06270142			17 Jan 2026	Pending	Biovail Laboratories International SRL	

PATENT

BIOVAIL MATERIAL PATENT PORTFOLIO

Biovail Case Reference	Title	Country /Region	Filing Date	Filing Number	Grant Date	Grant Number	Expiration Date	Current Status	Registered Owners	Notes
P003-SC-PCT	MODIFIED RELEASE TABLET OF BUPROPION HYDROCHLORIDE	Seychelles	08 Aug 2003	PCT2003/024700	08 May 2008	PCT2003/024700	08 Aug 2023	Granted	Biovail Laboratories International SRL	
P003-SD-AFT	MODIFIED RELEASE TABLET OF BUPROPION HYDROCHLORIDE	Sudan			31 Oct 2008	AP1899	08 Aug 2023	Granted	Biovail Laboratories International SRL	
P003-SG-PCT	MODIFIED RELEASE TABLET OF BUPROPION HYDROCHLORIDE	Singapore	08 Aug 2003	200600214-1	30 Jan 2009	131136[WO2005016318]	08 Aug 2023	Granted	Biovail Laboratories International SRL	
P003-SL-AFT	MODIFIED RELEASE TABLET OF BUPROPION HYDROCHLORIDE	Sierra Leone			31 Oct 2008	AP1899	08 Aug 2023	Granted	Biovail Laboratories International SRL	
P003-SZ-AFT	MODIFIED RELEASE TABLET OF BUPROPION HYDROCHLORIDE	Swaziland			31 Oct 2008	AP1899	08 Aug 2023	Granted	Biovail Laboratories International SRL	
P003-TN-PCT	MODIFIED RELEASE TABLET OF BUPROPION HYDROCHLORIDE	Tunisia	08 Aug 2003	SN06.016			08 Aug 2023	Pending	Biovail Laboratories International SRL	

PATENT

BIOVAIL MATERIAL PATENT PORTFOLIO										
Biovail Case Reference	Title	Country /Region	Filing Date	Filing Number	Grant Date	Grant Number	Expiration Date	Current Status	Registered Owners	Notes
P003-TT-PCT	MODIFIED RELEASE TABLET OF BUPROPION HYDROCHLORIDE	Trinidad And Tobago	08 Aug 2003	TT/A/2006/00014			08 Aug 2023	Pending	Biovail Laboratories International SRL	
P003-TZ-AFT	MODIFIED RELEASE TABLET OF BUPROPION HYDROCHLORIDE	Tanzania (United Republic Of)			31 Oct 2008	AP1899	08 Aug 2023	Granted	Biovail Laboratories International SRL	
P003-UA-PCT	MODIFIED RELEASE TABLET OF BUPROPION HYDROCHLORIDE	Ukraine	08 Aug 2003	a200601245			08 Aug 2023	Pending	Biovail Laboratories International SRL	
P003-UG-AFT	MODIFIED RELEASE TABLET OF BUPROPION HYDROCHLORIDE	Uganda			31 Oct 2008	AP1899	08 Aug 2023	Granted	Biovail Laboratories International SRL	
P003-US-CNT	MODIFIED RELEASE TABLET OF BUPROPION HYDROCHLORIDE	United States Of America	13 Jun 2006	11/451,496			08 Aug 2023 + 302 days PTA as per 35 USC 154(b)	To grant on May 26, 2009.	Biovail Laboratories International SRL	
P003-UZ-PCT	MODIFIED RELEASE TABLET OF BUPROPION HYDROCHLORIDE	Uzbekistan	08 Aug 2003	IAP 2006 0035			08 Aug 2023	Pending	Biovail Laboratories International SRL	

PATENT

Error! Unknown document property name.

BIOVAIL MATERIAL PATENT PORTFOLIO										
Biovail Case Reference	Title	Country /Region	Filing Date	Filing Number	Grant Date	Grant Number	Expiration Date	Current Status	Registered Owners	Notes
P003-VN-PCT	MODIFIED RELEASE TABLET OF BUPROPION HYDROCHLORIDE	Vietnam	08 Aug 2003	1200501719			08 Aug 2023	Pending	Biovail Laboratories International SRL	
P003-YU-PCT	MODIFIED RELEASE TABLET OF BUPROPION HYDROCHLORIDE	Serbia & Montenegro	08 Aug 2003	P-2006/0132			08 Aug 2023	Pending	Biovail Laboratories International SRL	
P003-ZA-PCT	MODIFIED RELEASE TABLET OF BUPROPION HYDROCHLORIDE	South Africa	08 Aug 2003	2005/09051	28 Mar 2007	2005/09051	08 Aug 2023	Granted	Biovail Laboratories International SRL	
P003-ZM-AFT	MODIFIED RELEASE TABLET OF BUPROPION HYDROCHLORIDE	Zambia			31 Oct 2008	AP1899	08 Aug 2023	Granted	Biovail Laboratories International SRL	
P003-ZW-AFT	MODIFIED RELEASE TABLET OF BUPROPION HYDROCHLORIDE	Zimbabwe			31 Oct 2008	AP1899	08 Aug 2023	Granted	Biovail Laboratories International SRL	
P0048 family relates to APLENZIN in the US. Only the P048-US-NP and related US applications/patents (CONS, DIVs, and CIPs) have been licensed to Sanofi-Aventis.										
P048-AR-P	BUPROPION HYDROBROMIDE AND MEDICAMENTS AND USES THEREOF	Argentina	19 Dec 2007	P070105745			19 Dec 2027	Pending	Biovail Laboratories International SRL	

PATENT

BIOVAIL MATERIAL PATENT PORTFOLIO										
Biovail Case Reference	Title	Country /Region	Filing Date	Filing Number	Grant Date	Grant Number	Expiration Date	Current Status	Registered Owners	Notes
P048-AU-PCT	BUPROPION HYDROBROMIDE AND USES THEREOF	Australia	27 Jun 2006	2006261788			27 Jun 2026	Pending	Biovail Laboratories International SRL	
P048-CA-PCT	BUPROPION HYDROBROMIDE AND USES THEREOF	Canada	27 Jun 2006	2,578,626			27 Jun 2026	Pending	Biovail Laboratories International SRL	
P048-CA-PCT[2]	BUPROPION HYDROBROMIDE AND USES THEREOF	Canada	27 Jun 2006	not yet known			27 Jun 2026	Pending	Biovail Laboratories International SRL	
P048-CN-PCT	BUPROPION HYDROBROMIDE AND USES THEREOF	China	27 Jun 2006	200680023265.7			27 Jun 2026	Pending	Biovail Laboratories International SRL	
P048-CO-PCT	BUPROPION HYDROBROMIDE AND USES THEREOF	Colombia	27 Jun 2006	07136836			27 Jun 2026	Pending	Biovail Laboratories International SRL	
P048-CR-PCT	BUPROPION HYDROBROMIDE AND USES THEREOF	Costa Rica	27 Jun 2006	9609			27 Jun 2026	Pending	Biovail Laboratories International SRL	

PATENT

BIOVAIL MATERIAL PATENT PORTFOLIO

Biovail Case Reference	Title	Country /Region	Filing Date	Filing Number	Grant Date	Grant Number	Expiration Date	Current Status	Registered Owners	Notes
P048-EC-PCT	BUPROPION HYDROBROMIDE AND MEDICAMENTS AND USES THEREOF	Ecuador	27 Jun 2006	SP-07-7999			11 Dec 2027	Pending	Biovail Laboratories International SRL	
P048-EP-EPT	BUPROPION HYDROBROMIDE AND MEDICAMENTS AND USES THEREOF	European Procedure (Patents)	27 Jun 2006	06774022.5			27 Jun 2026	Pending	Biovail Laboratories International SRL	
P048-EP-EPT[2]	BUPROPION HYDROBROMIDE AND MEDICAMENTS AND USES THEREOF	European Procedure (Patents)	26 Jun 2007	07736118.6			26 Jun 2027	Pending	Biovail Laboratories International SRL	
P048-IL-PCT	BUPROPION HYDROBROMIDE AND MEDICAMENTS AND USES THEREOF	Israel	27 Jun 2006	185760			27 Jun 2026	Pending	Biovail Laboratories International SRL	
P048-IN-PCT	BUPROPION HYDROBROMIDE AND MEDICAMENTS AND USES THEREOF	India	27 Jun 2006	8974/DELNP/2007			27 Jun 2026	Pending	Biovail Laboratories International SRL	
P048-JP-PCT	BUPROPION HYDROBROMIDE AND MEDICAMENTS AND USES THEREOF	Japan	27 Jun 2006	2008-519460			27 Jun 2026	Pending	Biovail Laboratories International SRL	

PATENT

BIOVAIL MATERIAL PATENT PORTFOLIO

Biovail Case Reference	Title	Country /Region	Filing Date	Filing Number	Grant Date	Grant Number	Expiration Date	Current Status	Registered Owners	Notes
P048-KR-PCT	BUPROPION HYDROBROMIDE AND MEDICAMENTS AND USES THEREOF	South Korea / Republic of Korea	27 Jun 2006	2007-7028784			27 Jun 2026	Pending	Biovail Laboratories International SRL	
P048-MX-PCT	BUPROPION HYDROBROMIDE AND MEDICAMENTS AND USES THEREOF	Mexico	27 Jun 2006	MX/a/2007/015016			27 Jun 2026	Pending	Biovail Laboratories International SRL	
P048-MY-NP	BUPROPION HYDROBROMIDE AND MEDICAMENTS AND USES THEREOF	Malaysia	19 Sep 2007	PI20071571			19 Sep 2027	Pending	Biovail Laboratories International SRL	
P048-NI-PCT	BUPROPION HYDROBROMIDE AND MEDICAMENTS AND USES THEREOF	Nicaragua	27 Jun 2006	2007/03221			27 Jun 2026	Pending	Biovail Laboratories International SRL	
P048-NZ-PCT	BUPROPION HYDROBROMIDE AND MEDICAMENTS AND USES THEREOF	New Zealand	27 Jun 2006	561375			27 Jun 2026	Pending	Biovail Laboratories International SRL	
P048-RU-PCT	BUPROPION HYDROBROMIDE AND MEDICAMENTS AND USES THEREOF	Russian Federation	27 Jun 2006	2007147343			27 Jun 2026	Pending	Biovail Laboratories International SRL	

PATENT

BIOVAIL MATERIAL PATENT PORTFOLIO

Biovail Case Reference	Title	Country /Region	Filing Date	Filing Number	Grant Date	Grant Number	Expiration Date	Current Status	Registered Owners	Notes
P048-SG-PCT	BUPROPION HYDROBROMIDE AND MEDICAMENTS AND USES THEREOF	Singapore	27 Jun 2006	200706599-8			27 Jun 2026	Pending	Biovail Laboratories International SRL	
P048-US-CIP	BUPROPION HYDROBROMIDE AND MEDICAMENTS AND USES THEREOF	United States Of America	07 Aug 2007	11/834,848			27 Jun 2025	Pending	Biovail Laboratories International SRL	
P048-US-CIP[2]	BUPROPION HYDROBROMIDE AND MEDICAMENTS AND USES THEREOF	United States Of America	31 Oct 2007	11/930,644			31 Oct 2027	Pending	Biovail Laboratories International SRL	
P048-US-CNT	BUPROPION HYDROBROMIDE AND MEDICAMENTS AND USES THEREOF	United States Of America	22 May 2007	11/751,768			27 Jun 2026	Notice of Allowance Received March 24, 2009	Biovail Laboratories International SRL	
P048-US-CNT[10]	BUPROPION HYDROBROMIDE AND MEDICAMENTS AND USES THEREOF	United States Of America	21 Jun 2007	11/766,239			27 Jun 2026	Pending	Biovail Laboratories International SRL	
P048-US-CNT[11]	BUPROPION HYDROBROMIDE AND MEDICAMENTS AND USES THEREOF	United States Of America	21 Jun 2007	11/766,251			27 Jun 2026	Pending	Biovail Laboratories International SRL	

PATENT

BIOVAIL MATERIAL PATENT PORTFOLIO

Biovail Case Reference	Title	Country /Region	Filing Date	Filing Number	Grant Date	Grant Number	Expiration Date	Current Status	Registered Owners	Notes
P048-US-CNT[12]	BUPROPION HYDROBROMIDE AND MEDICAMENTS AND USES THEREOF	United States Of America	06 Jul 2007	11774,109			27 Jun 2026	Pending	Biovail Laboratories International SRL	
P048-US-CNT[2]	BUPROPION HYDROBROMIDE AND MEDICAMENTS AND USES THEREOF	United States Of America	22 May 2007	11751,785			27 Jun 2026	Notice of Allowance Received March 13, 2009	Biovail Laboratories International SRL	
P048-US-CNT[3]	BUPROPION HYDROBROMIDE AND MEDICAMENTS AND USES THEREOF	United States Of America	31 May 2007	11755,946			27 Jun 2026	Notice of Allowance Received Feb 25, 2009	Biovail Laboratories International SRL	
P048-US-CNT[4]	BUPROPION HYDROBROMIDE AND MEDICAMENTS AND USES THEREOF	United States Of America	07 Jun 2007	11759,413			27 Jun 2026	Pending	Biovail Laboratories International SRL	
P048-US-CNT[5]	BUPROPION HYDROBROMIDE AND MEDICAMENTS AND USES THEREOF	United States Of America	13 Jun 2007	11762,368			27 Jun 2026	Pending	Biovail Laboratories International SRL	
P048-US-CNT[6]	BUPROPION HYDROBROMIDE AND MEDICAMENTS AND USES THEREOF	United States Of America	13 Jun 2007	11762,343			27 Jun 2026	Pending	Biovail Laboratories International SRL	

PATENT

BIOVAIL MATERIAL PATENT PORTFOLIO

Biovail Case Reference	Title	Country /Region	Filing Date	Filing Number	Grant Date	Grant Number	Expiration Date	Current Status	Registered Owners	Notes
P048-US-CNT[7]	BUPROPION HYDROBROMIDE AND MEDICAMENTS AND USES THEREOF	United States Of America	14 Jun 2007	11/762,820			27 Jun 2026	Notice of Allowance Received March 18, 2009	Biovail Laboratories International SRL	
P048-US-CNT[8]	BUPROPION HYDROBROMIDE AND MEDICAMENTS AND USES THEREOF	United States Of America	14 Jun 2007	11/762,840			27 Jun 2026	Notice of Allowance Received May 12, 2009	Biovail Laboratories International SRL	
P048-US-CNT[9]	BUPROPION HYDROBROMIDE AND MEDICAMENTS AND USES THEREOF	United States Of America	21 Jun 2007	11/766,213			27 Jun 2026	Pending	Biovail Laboratories International SRL	
P048-US-NP	BUPROPION HYDROBROMIDE AND MEDICAMENTS AND USES THEREOF	United States Of America	27 Jun 2006	11/475,252	10 Jul 2007	7,241,805	27 Jun 2025	Granted	Biovail Laboratories International SRL	
P048-US-PCT	BUPROPION HYDROBROMIDE AND MEDICAMENTS AND USES THEREOF	United States Of America	27 Jun 2006	11/993,723			27 Jun 2026	Pending	Biovail Laboratories International SRL	
P048-WO-BCT[3]	BUPROPION HYDROBROMIDE AND MEDICAMENTS AND USES THEREOF	International Procedure	06 Aug 2008	PCT/EP2008/060361				Pending	Biovail Laboratories International SRL	

PATENT

BIOVAIL MATERIAL PATENT PORTFOLIO

Biovail Case Reference	Title	Country /Region	Filing Date	Filing Number	Grant Date	Grant Number	Expiration Date	Current Status	Registered Owners	Notes
P048-WO-PCT[4]	BUPROPION HYDROBROMIDE AND MEDICAMENTS AND USES THEREOF	International Procedure	28 Oct 2008	PCT/EP2008/064619				Pending	Biovail Laboratories International SRL	
P048-ZA-PCT	BUPROPION HYDROBROMIDE AND MEDICAMENTS AND USES THEREOF	South Africa	27 Jun 2006	2007/11123			27 Jun 2026	Pending	Biovail Laboratories International SRL	

P049 family relates to ULTRAM ER in the US and RALIVIA in Canada. Only P048-US-PCT, P048-US-CNT1 and P048-US-CIP have been licensed to OMI.

P049-AU-PCT	MODIFIED RELEASE FORMULATIONS OF AT LEAST ONE FORM OF TRAMADOL	Australia	21 Feb 2003	2003211145	01 Nov 2007	2003211145	21 Feb 2023	Granted	Biovail Laboratories International SRL	
P049-CA-PCT	MODIFIED RELEASE FORMULATIONS OF AT LEAST ONE FORM OF TRAMADOL	Canada	21 Feb 2003	2476201			21 Feb 2023	Pending	Biovail Laboratories International SRL	
P049-EP-EPT	MODIFIED RELEASE FORMULATIONS OF AT LEAST ONE FORM OF TRAMADOL	European Procedure (Patents)	21 Feb 2003	03743147.5			21 Feb 2023	Pending	Biovail Laboratories International SRL	
P049-IN-PCT	MODIFIED RELEASE FORMULATIONS OF AT LEAST ONE FORM OF TRAMADOL	India	21 Feb 2003	1187/KOLNP/2004			21 Feb 2023	Pending	Biovail Laboratories International SRL	

PATENT

Error! Unknown document property name.

BIOVAIL MATERIAL PATENT PORTFOLIO										
Biovail Case Reference	Title	Country /Region	Filing Date	Filing Number	Grant Date	Grant Number	Expiration Date	Current Status	Registered Owners	Notes
P049-JP-PCT	MODIFIED RELEASE FORMULATIONS OF AT LEAST ONE FORM OF TRAMADOL	Japan	21 Feb 2003	2003-570772			21 Feb 2023	Pending	Biovail Laboratories Inc. ¹	Pending Registration of Assignment to Biovail Laboratories International SRL
P049-MX-PCT	MODIFIED RELEASE FORMULATIONS OF AT LEAST ONE FORM OF TRAMADOL	Mexico	21 Feb 2003	PA/a/2004/008100	20 Feb 2008	254912	21 Feb 2023	Granted	Biovail Laboratories International SRL	
P049-NO-PCT	MODIFIED RELEASE FORMULATIONS OF AT LEAST ONE FORM OF TRAMADOL	Norway	21 Feb 2003	20043913			21 Feb 2023	Pending	Biovail Laboratories International SRL	
P049-NZ-PCT	MODIFIED RELEASE FORMULATIONS OF AT LEAST ONE FORM OF TRAMADOL	New Zealand	21 Feb 2003	535456	14 Dec 2006	535456	21 Feb 2023	Granted	Biovail Laboratories International SRL	
P049-US-CIP1	MODIFIED RELEASE FORMULATIONS OF AT LEAST ONE FORM OF TRAMADOL	United States Of America	03 Sep 2004	10/933479			21 Feb 2023	Pending	Biovail Laboratories International SRL	

PATENT

¹ Prior name of Biovail Laboratories International SRL

Error! Unknown document property name.

BIOVAIL MATERIAL PATENT PORTFOLIO

Biovail Case Reference	Title	Country /Region	Filing Date	Filing Number	Grant Date	Grant Number	Expiration Date	Current Status	Registered Owners	Notes
P049-US-CNT	MODIFIED RELEASE FORMULATIONS OF AT LEAST ONE FORM OF TRAMADOL	United States Of America	30 Oct 2007	11/928,908			21 Feb 2023	Pending	Biovail Laboratories International SRL	
P049-US-PCT	MODIFIED RELEASE FORMULATIONS OF AT LEAST ONE FORM OF TRAMADOL	United States Of America	11 Oct 2005	10/517809			11 Oct 2025	Pending	Biovail Laboratories International SRL	

P050 family relates to our AQ drug delivery technology platform. P050-US-NP, P050-US-CNT and P050-US-CIP cover the 1000mg GLUMETZA product in the US and Canada. The US IP is licensed to Depomed.

P050-AU-PCT	CONTROLLED RELEASE DOSAGE FORMS	Australia	21 Feb 2003	2003211146	01 Nov 2007	2003211146	21 Feb 2023	Granted	Biovail Laboratories International SRL	
P050-CA-PCT	CONTROLLED RELEASE DOSAGE FORMS	Canada	21 Feb 2003	2476496			21 Feb 2023	Pending	Biovail Laboratories International SRL	
P050-EP-EPT	CONTROLLED RELEASE DOSAGE FORMS	European Procedure (Patents)	21 Feb 2003	03743148.3			21 Feb 2023	Pending	Biovail Laboratories International SRL	

PATENT

BIOVAIL MATERIAL PATENT PORTFOLIO

Biovail Case Reference	Title	Country /Region	Filing Date	Filing Number	Grant Date	Grant Number	Expiration Date	Current Status	Registered Owners	Notes
P050-IN-PCT	CONTROLLED RELEASE DOSAGE FORMS	India	21 Feb 2003	1193/KOLNP/2004	11 Jun 2008	220994	21 Feb 2023	Granted	Biovail Laboratories International SRL	
P050-JP-PCT	CONTROLLED RELEASE DOSAGE FORMS	Japan	21 Feb 2003	2003-570835			21 Feb 2023	Pending	Biovail Laboratories Inc.	Pending Registration of Assignment to Biovail Laboratories International SRL
P050-MX-PCT	CONTROLLED RELEASE DOSAGE FORMS	Mexico	21 Feb 2003	PA/a/2004/008164	15 Aug 2007	248063	21 Feb 2023	Granted	Biovail Laboratories International SRL	
P050-NZ-PCT	CONTROLLED RELEASE DOSAGE FORMS	New Zealand	21 Feb 2003	535455			21 Feb 2023	Pending	Biovail Laboratories International SRL	
P050-US-CIP	CONTROLLED RELEASE DOSAGE FORMS	United States Of America	05 Dec 2008	12/328,828			21 Feb 2023	Pending	Biovail Laboratories International SRL	
P050-US-INT	CONTROLLED RELEASE DOSAGE FORMS	United States Of America	09 Jul 2008	12/169,852			21 Feb 2023	Pending	Biovail Laboratories International SRL	

PATENT

BIOVAIL MATERIAL PATENT PORTFOLIO

Biovail Case Reference	Title	Country /Region	Filing Date	Filing Number	Grant Date	Grant Number	Expiration Date	Current Status	Registered Owners	Notes
P050-US-NP	CONTROLLED RELEASE DOSAGE FORMS	United States Of America	21 Feb 2003	10/370109			21 Feb 2023	Pending	Biovail Laboratories International SRL	

P051 covers CARDIZEM-LA, but NOT for approved indication

P051-US-CNT	CHRONOTHERAPEUTIC DILTIAZEM FORMULATIONS AND THE ADMINISTRATION THEREOF	United States Of America	07 Dec 2007	11/952,343			09 Sep 2023	Pending	Biovail Laboratories International SRL	.
P051-US-NP	CHRONOTHERAPEUTIC DILTIAZEM FORMULATIONS AND THE ADMINISTRATION THEREOF	United States Of America	09 Sep 2003	10/657752	25 Mar 2008	7,348,028	09 Sep 2023	Granted	Biovail Laboratories International SRL	

P052 covers an alternative embodiment to GLUMETZA, which embodiment is NOT being commercialized nor are there any plans to commercialize thisP052 embodiment.

P052-AU-PCT	Extended Release Tablet of Metformin	Australia	04 Dec 2002	2002359582	03 May 2007	2002359582	04 Dec 2022	Granted	Biovail Laboratories International SRL	
P052-CA-PCT	Extended Release Tablet of Metformin	Canada	04 Dec 2002	2470747			04 Dec 2022	Pending	Biovail Laboratories International SRL	

PATENT

Error! Unknown document property name.

BIOVAIL MATERIAL PATENT PORTFOLIO										
Biovail Case Reference	Title	Country /Region	Filing Date	Filing Number	Grant Date	Grant Number	Expiration Date	Current Status	Registered Owners	Notes
P052-EP-EPT	Extended Release Tablet of Metformin	European Procedure (Patents)	02 Dec 2002	02794129.3			02 Dec 2022	Pending	Biovail Laboratories International SRL	
P052-HU-PCT	Extended Release Tablet of Metformin	Hungary	04 Dec 2002	P0500004			04 Dec 2022	Pending	Biovail Laboratories International SRL	
P052-IN-PCT	Extended Release Tablet of Metformin	India	02 Dec 2002	932/KOLNP/2004	08 Dec 2008	226125	02 Dec 2022	Granted	Biovail Laboratories International SRL	
P052-MX-PCT	Extended Release Tablet of Metformin	Mexico	02 Dec 2002	PA/a/2004/005667			02 Dec 2022	Pending	Biovail Laboratories International SRL	
P052-NO-PCT	Extended Release Tablet of Metformin	Norway	02 Dec 2002	20042822			02 Dec 2022	Pending	Biovail Laboratories International SRL	
P052-NZ-PCT	Extended Release Tablet of Metformin	New Zealand	02 Dec 2002	533857	13 Sep 2007	533857	02 Dec 2022	Granted	Biovail Laboratories International SRL	

PATENT

BIOVAIL MATERIAL PATENT PORTFOLIO

Biovail Case Reference	Title	Country /Region	Filing Date	Filing Number	Grant Date	Grant Number	Expiration Date	Current Status	Registered Owners	Notes
P052-US-CIP	Extended Release Tablet of Metformin	United States Of America	04 Dec 2002	10/309193			04 Dec 2021	Pending	Biovail Laboratories International SRL	
P052-US-CIP1	Extended Release Tablet of Metformin	United States Of America	04 Feb 2004	10/771987			04 Dec 2021	Pending	Biovail Laboratories International SRL	1

PATENT 055 is specific to Canada only and covers both TIAZAC and TIAZAC XC. TIAZAC has been genericized in Canada, TIAZAC XC has NOT been genericized yet nor has BLS received an NOA for this product. FYI, TIAZAC XC = CARDIZEM LA. Biovail does not own or license the US counterpart of this Canadian patent for CARDIZEM LA

PATENT

BIOVAIL MATERIAL PATENT PORTFOLIO

Biovail Case Reference	Title	Country /Region	Filing Date	Filing Number	Grant Date	Grant Number	Expiration Date	Current Status	Registered Owners	Notes
P055-CA-NP	SUSTAINED-RELEASE MICROGRANULES CONTAINING DILTIAZEM AS THE ACTIVE PRINCIPLE	Canada	23 Dec 1996	2242224	13 Jan 2004	2242224	23 Dec 2016	Granted	Biovail Laboratories International SRL	
<i>P062-CA-PCT covers both TIAZAC and TIAZAC XC in Canada.</i>										
<i>P062-US-CNT covers both TIAZAC and CARDIZEM LA in the US.</i>										
<i>P062-US-NP covers CARDIZEM LA only in the US.</i>										
P062-CA-PCT	EXTENDED RELEASE FORM OF DILTIAZEM	Canada	25 Jun 1992	2111085	27 Apr 1999	2111085	25 Jun 2012	Granted	Galephar Puerto Rico Inc., Limited; Biovail Research Corporation	Pending Registration of Assignment to Biovail Laboratories International SRL
P062-US-CNT	EXTENDED RELEASE FORM OF DILTIAZEM	United States Of America	23 Sep 1994	08/311722	26 Jun 1996	5529791	26 Jun 2013	Granted	Biovail Laboratories International SRL	

PATENT

Error! Unknown document property name.

BIOVAIL MATERIAL PATENT PORTFOLIO

Biovail Case Reference	Title	Country /Region	Filing Date	Filing Number	Grant Date	Grant Number	Expiration Date	Current Status	Registered Owners	Notes
P062-US-NP	EXTENDED RELEASE FORM OF DILTIAZEM	United States Of America	26 Jun 1991	07/721396	22 Feb 1994	5288505	26 Jun 2011	Granted	Biovail Laboratories International SRL	

P063 covers WELLBUTRIN XL in the US only. Foreign counterparts do not exist.

P063-US-CNT	DELAYED RELEASE TABLET OF BUPROPION HYDROCHLORIDE	United States Of America	13 Dec 1999	09/459459	07 Nov 2000	6143327	30 Oct 2018	Granted	Biovail Laboratories International SRL	
P063-US-NP	DELAYED RELEASE TABLET OF BUPROPION HYDROCHLORIDE	United States Of America	30 Oct 1998	09/184091	01 Aug 2000	6096341	30 Oct 2018	Granted	Biovail Laboratories International SRL	

P066 is specific to Canada only and does NOT cover any commercialized product, but is material to WELLBUTRIN XL in Canada as a defensive patent.

P066-CA-PCT	PHARMACEUTICAL COMPOSITION CONTAINING BUPROPION HYDROCHLORIDE AND AN INORGANIC ACID STABILIZER	Canada	23 Dec 1998	2316985	12 Jun 2007	2316985	23 Dec 2018	Granted	Biovail Laboratories International SRL	
-------------	--	--------	-------------	---------	-------------	---------	-------------	---------	--	--

PATENT

Error! Unknown document property name.

BIOVAIL MATERIAL PATENT PORTFOLIO

Biovail Case Reference	Title	Country /Region	Filing Date	Filing Number	Grant Date	Grant Number	Expiration Date	Current Status	Registered Owners	Notes
------------------------	-------	-----------------	-------------	---------------	------------	--------------	-----------------	----------------	-------------------	-------

P068 is specific to Canada only and does NOT cover any commercialized product, but is material to WELLBUTRIN XL in Canada as a defensive patent.

P068-CA-PCT	BUPROPION HYDROCHLORIDE/ORGANIC ACID STABILIZER	Canada	23 Dec 1998	2316981	07 Aug 2007	2,316,981	23 Dec 2018	Granted	Biovail Laboratories International SRL	
-------------	---	--------	-------------	---------	-------------	-----------	-------------	---------	--	--

P070 family MAY be relevant to our undisclosed BVF-045 product.

P070-CA-NP	MODIFIED RELEASE SSRI FORMULATIONS	Canada	24 Dec 2002	2415154			24 Dec 2022	Pending	Biovail Laboratories International SRL	
P070-EP-EPT	MODIFIED RELEASE SSRI FORMULATIONS	European Procedure (Patents)	19 Dec 2003	03788728.8			19 Dec 2023	Pending	Biovail Laboratories International SRL	
P070-US-PCT	MODIFIED RELEASE SSRI FORMULATIONS	United States Of America	19 Dec 2003	10/556,492			19 Dec 2023	Pending	Biovail Laboratories International SRL	

PATENT

P098 family covers CARDIZEM CD in the US.

Error! Unknown document property name.

BIOVAIL MATERIAL PATENT PORTFOLIO

Biovail Case Reference	Title	Country /Region	Filing Date	Filing Number	Grant Date	Grant Number	Expiration Date	Current Status	Registered Owners	Notes
P098-US-CNT	DILTIAZEM FORMULATION	United States Of America	06 May 1993	08/058,534	15 Feb 1994	5,286,497	20 May 2011	Granted	Biovail Laboratories International SRL	
P098-US-CNT[2]	DILTIAZEM FORMULATION	United States Of America	27 Feb 1995	08/394,573	28 Nov 1995	5,470,584	28 Nov 2012	Granted	Biovail Laboratories International SRL	
P098-US-CNT1	DILTIAZEM FORMULATION	United States Of America	08 Dec 1993	08/164,062	08 Aug 1995	5,439,689	08 Aug 2012	Granted	Biovail Laboratories International SRL	

P100 family covers CARDIZEM LA for the allowed indication.

P100-CA-DIV	CHRONOTHERAPEUTIC FORMULATIONS OF DILTIAZEM AND THE ADMINISTRATION THEREOF	Canada	22 Nov 2006	2,566,590	15 Apr 2008	2,566,590	04 May 2020	Granted	Biovail Laboratories International SRL	
P100-CA-IMP1	CHRONOTHERAPEUTIC FORMULATIONS OF DILTIAZEM AND THE ADMINISTRATION THEREOF	Canada	04 May 2000	2,307,547	14 Aug 2007	2,307,547	04 May 2020	Granted	Biovail Laboratories International SRL	

PATENT

Error! Unknown document property name.

BIOVAIL MATERIAL PATENT PORTFOLIO

Biovail Case Reference	Title	Country /Region	Filing Date	Filing Number	Grant Date	Grant Number	Expiration Date	Current Status	Registered Owners	Notes
P100-EP-EPT	CHRONOTHERAPEUTIC FORMULATIONS OF DILTIAZEM AND THE ADMINISTRATION THEREOF	European Procedure (Patents)	23 May 2000	00930909.7			23 May 2020	Pending	Biovail Laboratories International SRL	
P100-JP-PCT	CHRONOTHERAPEUTIC FORMULATIONS OF DILTIAZEM AND THE ADMINISTRATION THEREOF	Japan	23 May 2000	PCT/CA00/00593			23 May 2020	Pending	Biovail Laboratories International SRL	
P100-US-NP1	CHRONOTHERAPEUTIC FORMULATIONS OF DILTIAZEM AND THE ADMINISTRATION THEREOF	United States Of America	08 May 2000	09/567,451	19 Sep 2006	7,108,866	08 May 2020	Granted	Biovail Laboratories International SRL	
P112 covers an alternative embodiment for GLUMETZA										
P112-US-NP	EXTENDED RELEASE METFORMIN HYDROCHLORIDE FORMULATIONS	United States Of America	01 May 2001	09/845,496	13 Jan 2004	6,676,966	09 May 2020	Granted	Biovail Laboratories International SRL	
P144 covers BVF045										
P144-US-NP	PHARMACEUTICAL COMPOSITIONS	United States Of America	28 Jan 2009	12/360,673			28 Jan 2029	Pending	Biovail Laboratories International SRL	

PATENT

BIOVAIL MATERIAL PATENT PORTFOLIO

Biovail Case Reference	Title	Country /Region	Filing Date	Filing Number	Grant Date	Grant Number	Expiration Date	Current Status	Registered Owners	Notes
P144-WO-PCT	PHARMACEUTICAL COMPOSITIONS	International Procedure	28 Jan 2009	PCT/EP2009/050924				Pending	Biovail Laboratories International SRL	

P145 covers WELLBUTRIN SR and WELLBUTRIN XL in Canada.

P145-CA-PCT	SUSTAINED RELEASE TABLETS CONTAINING BUPROPION	Canada	13 Aug 1993	2142320	09 Oct 2001	2142320	13 Aug 2013	Granted	THE WELLCOME FOUNDATION LIMITED	Pending Registration of Assignment to Biovail Laboratories International SRL
-------------	--	--------	-------------	---------	-------------	---------	-------------	---------	---------------------------------	--

P146 covers WELLBUTRIN SR and WELLBUTRIN XL in Canada.

PATENT

BIOVAIL MATERIAL PATENT PORTFOLIO										
Biovail Case Reference	Title	Country /Region	Filing Date	Filing Number	Grant Date	Grant Number	Expiration Date	Current Status	Registered Owners	Notes
P146-CA-PCT	STABILIZED PHARMACEUTICAL COMPOSITION CONTAINING BUPROPION	Canada	29 Jul 1994	2168364	18 Sep 2001	2168364	29 Jul 2014	Granted	THE WELLCOME FOUNDATION LIMITED	Pending Registration of Assignment to Biovail Laboratories International SRL

SCHEDULE B

TRADEMARKS & SERVICE MARKS

(including registrations and applications and exclusive and nonexclusive licenses)

See attached.

BOS111 12386775.4

Error! Unknown document property name.

PATENT
REEL: 022813 FRAME: 0246

BIOVAIL TRADEMARK PORTFOLIO

Biovail Case Reference	Trademark	Country	Filing Date	Filing Number	Registration Date	Registration Number	Current Status	Registered Owners	Notes
T005-US-NF	A (A Tablet design - Apex down)	United States Of America	31 May 1983	73428249	26 Jun 1984	1283003	Registration	Biovail Laboratories International SRL	
T006-US-NF	A (A Tablet design - Apex Up)	United States Of America	24 Dec 1981	73343230	18 Oct 1983	1254277	Registration	Biovail Laboratories International SRL	
T094-CA-NF	APLENZIN	Canada	24 Oct 2007	1,369,029			Pending	Biovail Laboratories International SRL	
T101-AR-NF	APLENZIN	Argentina	28 Jan 2009	2890864			Pending	Biovail Laboratories International SRL	
T101-AU-NF	APLENZIN	Australia	27 Nov 2008	1274549			Pending	Biovail Laboratories International SRL	
T101-BB-NF	APLENZIN	Barbados	31 Jul 2008	81/24871			Pending	Biovail Laboratories International SRL	
T101-CN-NF	APLENZIN	China	08 Dec 2008	7100795			Pending	Biovail Laboratories International SRL	
T101-CO-NF	APLENZIN	Colombia	09 Dec 2008	08-130235			Pending	Biovail Laboratories International SRL	
T101-CR-NF	APLENZIN	Costa Rica	15 Jan 2009	2009-000281			Pending	Biovail Laboratories International SRL	

PATENT

BOS111 12386775.4

Error! Unknown document property name.

Biovail Case Reference	Trademark	Country	Filing Date	Filing Number	Registration Date	Registration Number	Current Status	Registered Owners	Notes
T101-EC-NF	APLENZIN	Ecuador	01 Dec 2008	207982			Pending	Biovail Laboratories International SRL	
T101-EU-CTM	APLENZIN	European Union	01 Dec 2008	7462799			Pending	Biovail Laboratories International SRL	
T101-IL-NF	APLENZIN	Israel	30 Nov 2008	216969			Pending	Biovail Laboratories International SRL	
T101-IN-NF	APLENZIN	India	15 Jan 2009	1774270			Pending	Biovail Laboratories International SRL	
T101-JP-NF	APLENZIN	Japan	02 Dec 2008	2008-097001			Pending	Biovail Laboratories International SRL	
T101-KR-NF	APLENZIN	South Korea / Republic of Korea	29 Jan 2009	40-2009-0003901			Pending	Biovail Laboratories International SRL	
T101-MX-NF	APLENZIN	Mexico	20 Jan 2009	984765			Pending	Biovail Laboratories International SRL	
T101-MY-NF	APLENZIN	Malaysia	16 Dec 2008	2008/24684			Pending	Biovail Laboratories International SRL	
T101-NI-NF	APLENZIN	Nicaragua	09 Dec 2008	2008/04292			Pending	Biovail Laboratories International SRL	
T101-NZ-NF	APLENZIN	New Zealand	27 Nov 2008	799614			Pending	Biovail Laboratories International SRL	
T101-RU-NF	APLENZIN	Russian Federation	13 Jan 2009	2009700282			Pending	Biovail Laboratories International SRL	
T101-SG-NF	APLENZIN	Singapore	10 Dec 2008	T0817142I			Pending	Biovail Laboratories International SRL	

PATENT

BOS111 12386775.4

Error! Unknown document property name.

Biovail Case Reference	Trademark	Country	Filing Date	Filing Number	Registration Date	Registration Number	Current Status	Registered Owners	Notes
T101-ZA-NF	APLENZIN	South Africa	03 Dec 2008	2008/28353			Pending	Biovail Laboratories International SRL	
T009-CA-NF	ASOLZA	Canada	29 Sep 2006	1318519			Pending	Biovail Laboratories International SRL	
T009-US-NF	ASOLZA	United States Of America	31 Mar 2006	78851378			Pending	Biovail Laboratories International SRL	
T008-US-NF	ATIVAN	United States Of America	12 Jan 1968	72288666	19 Aug 1969	875020	Registration	Biovail Laboratories International SRL	
T055-CA-NF	ATTENADE	Canada	09 Jul 2003	1183835			Pending	Biovail Laboratories International SRL	
T076-HK-NF	BIOVAIL	Hong Kong	14 May 2007	300870462			Pending	Biovail Laboratories International SRL	
T079-TW-NF	BIOVAIL	Taiwan	15 Jun 2007	096028733			Pending	Biovail Laboratories International SRL	
T012-US-NF	BPI	United States Of America	13 Jun 2003	78262407			Pending	Biovail Laboratories Inc. ²	
T013-US-NF	BPI	United States Of America	13 Jun 2003	78976515	27 Dec 2005	3036881	Registration	Biovail Laboratories Inc.	
T014-US-NF	BVF	United States Of America	21 May 2003	78252577	12 Jul 2005	2966250	Registration	Biovail Laboratories International SRL	
T072-US-NF	CARDISENSE	United States Of America	16 May 2007	77182237			Pending	Biovail Laboratories International SRL	

PATENT

² Prior name of Biovail Laboratories International SRL

BOS111 12386775.4

Error! Unknown document property name.

Biovail Case Reference	Trademark	Country	Filing Date	Filing Number	Registration Date	Registration Number	Current Status	Registered Owners	Notes
T083-CN-NF	CARDISENSE	China	18 Jun 2007	6114269			Pending	Biovail Laboratories International SRL	
T084-CN-NF	CARDISENSE	China	18 Jun 2007	6114270			Pending	Biovail Laboratories International SRL	
T085-CN-NF	CARDISENSE	China	18 Jun 2007	6114271			Pending	Biovail Laboratories International SRL	
T073-BB-NF	CARDISENSE (16)	Barbados	10 Apr 2007	81/22924			Pending	Biovail Laboratories International SRL	
T074-BB-NF	CARDISENSE (41)	Barbados	10 Apr 2007	81/22925			Pending	Biovail Laboratories International SRL	
T072-BB-NF	CARDISENSE (9)	Barbados	10 Apr 2007	81/22923			Pending	Biovail Laboratories International SRL	
T072-CA-NF	CARDISENSE (9)	Canada	17 May 2007	1,347,905			Pending	Biovail Laboratories International SRL	
T073-HK-NF	CARDISENSE (English)	Hong Kong	15 Jun 2007	300893511	15 Jun 2007	300893511	Registration	Biovail Laboratories International SRL	
T015-CA-NF	CARDIZEM	Canada	16 Nov 1981	0478379	13 May 1983	TMA279505	Registration	sanofi-aventis U.S. LLC	Pending Registration of Assignment to BLS
T015-US-NF	CARDIZEM	United States Of America	22 Jan 1981	73293970	26 Jul 1983	1246194	Registration	Biovail Laboratories International SRL	
T016-US-NF	CARDIZEM	United States Of America	04 Dec 1986	73633651	30 Jun 1987	1444842	Registration	Biovail Laboratories International SRL	
T086-CN-NF	CARDIZEM	China	18 Jun 2007	6114268			Pending	Biovail Laboratories International SRL	

PATENT

BOS111 12386775.4

Error! Unknown document property name.

Biovail Case Reference	Trademark	Country	Filing Date	Filing Number	Registration Date	Registration Number	Current Status	Registered Owners	Notes
T077-HK-NF	CARDIZEM (Chinese characters)	Hong Kong	15 Jun 2007	300893520	15 Jun 2007	300893520	Registration	Biovail Laboratories International SRL	
T078-HK-NF	CARDIZEM (Chinese characters)	Hong Kong	15 Jun 2007	300893520			Pending	Biovail Laboratories International SRL	
T087-CN-NF	CARDIZEM (Chinese Characters)	China	18 Jun 2007	6114272			Pending	Biovail Laboratories International SRL	
T077-HK-NF[2]	CARDIZEM (English)	Hong Kong	13 Jun 2007	300891469	13 Jun 2007	300891469	Registration	Biovail Laboratories International SRL	
T099-EU-CTM	CEFORM	European Union	30 Jul 1998	000892398	20 Jan 2001	000892398	Registration	Biovail Laboratories International SRL	
T056-CA-NF	DITECH	Canada	29 Dec 2004	1242140			Pending	Biovail Laboratories International SRL	
T019-AT-NF	FLASHDOSE	Austria	05 Sep 1994	AM4460/94	07 Jun 1995	158046	Registration	Biovail Laboratories Inc.	
T019-AU-NF	FLASHDOSE	Australia	29 Aug 1994	639069	29 Aug 1994	639069	Registration	Biovail Laboratories International SRL	
T019-BX-NF	FLASHDOSE	Benelux	29 Aug 1994	832.881	31 Aug 2004	559011	Registration	Biovail Laboratories Inc.	
T019-CA-NF	FLASHDOSE	Canada	01 Sep 1994	763119	24 May 1996	457855	Registration	Biovail Laboratories Inc.	
T019-CH-NF	FLASHDOSE	Switzerland	02 Sep 1994	5988/1994.4	05 Jun 1996	423.579	Registration	Biovail Laboratories Inc.	
T019-DK-NF	FLASHDOSE	Denmark	31 Aug 1994	VA 06.044/94	04 Nov 1994	VR 07.515 1994	Registration	Biovail Laboratories Inc.	
T019-ES-NF	FLASHDOSE	Spain	06 Sep 1994	1920089	05 Apr 1995	1920089	Registration	Biovail Laboratories Inc.	

BOS111 12385775.4

PATENT

Error! Unknown document property name.

Biovail Case Reference	Trademark	Country	Filing Date	Filing Number	Registration Date	Registration Number	Current Status	Registered Owners	Notes
T019-EU-CTM	FLASHDOSE	European Union	22 Jun 2005	004512364	07 Aug 2006	004512364	Registration	Biovail Laboratories International SRL	
T019-FI-NF	FLASHDOSE	Finland	02 Sep 1994	4395/94	06 Nov 1995	140650	Registration	Biovail Laboratories Inc.	
T019-FR-NF	FLASHDOSE	France	07 Sep 1994	94/535213	10 Jan 1995	94/535213	Registration	Biovail Laboratories International SRL	
T019-GB-NF	FLASHDOSE	United Kingdom	31 Aug 1994	1583283	08 Mar 1994	B1583283	Registration	Biovail Laboratories International SRL	
T019-HU-NF	FLASHDOSE	Hungary	30 Aug 1994	M9403209	30 Aug 1994	143976	Registration	Biovail Laboratories International SRL	
T019-IE-NF	FLASHDOSE	Ireland	30 Aug 1994	5459/94	08 Mar 1994	164335	Registration	Biovail Laboratories Inc.	
T019-JP-NF	FLASHDOSE	Japan	08 Sep 1994	6-091584	13 Mar 1997	08/128428	Registration	Biovail Laboratories Inc.	
T019-NO-NF	FLASHDOSE	Norway	01 Sep 1994	94.4857	27 Jun 1996	174604	Registration	Biovail Laboratories International SRL	
T019-PL-NF	FLASHDOSE	Poland	30 Aug 1994	Z137503	19 May 2000	120909	Registration	Biovail Laboratories International SRL	
T019-SE-NF	FLASHDOSE	Sweden	08 Sep 1994	94-08948	02 Jun 1995	302.578	Registration	Biovail Laboratories International SRL	
T019-TW-NF	FLASHDOSE	Taiwan	01 Sep 1994	83-56299	01 Nov 1995	694584	Registration	Biovail Laboratories International SRL	
T019-US-NF	FLASHDOSE	United States Of America	08 Mar 1994	74498162	25 Mar 1997	2048066	Registration	Biovail Laboratories Inc.	
T020-US-NF	FLASHDOSE	United States Of America	07 Jan 2005	78543928			Pending	Biovail Laboratories International SRL	

BOS111 12386775.4

PATENT

Error! Unknown document property name.

Biovail Case Reference	Trademark	Country	Filing Date	Filing Number	Registration Date	Registration Number	Current Status	Registered Owners	Notes
T054-BB-NF	FLASHDOSE	Barbados	24 Oct 2006	81/22348			Pending	Biovail Laboratories International SRL	
T066-CA-NF	FLASHDOSE	Canada	01 Sep 1994	763119	24 May 1996	457855	Registration	Biovail Laboratories International SRL	
T021-CA-NF	GLUMETZA	Canada	16 Apr 2004	1213583	25 Sep 2006	673214	Registration	Biovail Laboratories International SRL	
T021-US-NF	GLUMETZA	United States Of America	12 Dec 2003	78340355	08 Jan 2008	3,366,577	Registration	Biovail Laboratories International SRL	
T022-US-NF	HEALTHBURST	United States Of America	20 Jun 2003	78265254			Pending	Biovail Laboratories International SRL	
T023-US-NF	INSTATAB	United States Of America	17 Jul 2006	78931095			Pending	Biovail Laboratories International SRL	
T049-BB-NF	INSTATAB	Barbados	15 Aug 2006	81/22115			Pending	Biovail Laboratories International SRL	
T026-PR-NF	ISORDIL	Porto Rico	13 Mar 1962	12102	13 Mar 1962	12102	Registration	AMERICAN HOME PRODUCTS (WYETH)	Licensed to BLS
T026-US-NF	ISORDIL	United States Of America	23 Sep 1959	72081865	03 May 1960	0697014	Registration	Biovail Laboratories International SRL	
T024-CA-NF	JOVOLA	Canada	29 Sep 2006	1318521			Pending	Biovail Laboratories International SRL	
T024-US-NF	JOVOLA	United States Of America	17 Apr 2006	78862891			Pending	Biovail Laboratories International SRL	
T027-CA-NF	JUBLIA	Canada	29 Sep 2006	1318522			Pending	Biovail Laboratories International SRL	
T027-US-NF	JUBLIA	United States Of America	17 Apr 2006	78862951			Pending	Biovail Laboratories International SRL	

BOS111 12386775.4

PATENT

Error! Unknown document property name.

Biovail Case Reference	Trademark	Country	Filing Date	Filing Number	Registration Date	Registration Number	Current Status	Registered Owners	Notes
T028-CA-NF	MIVURA	Canada	29 Sep 2006	1318515			Pending	Biovail Laboratories International SRL	
T028-US-NF	MIVURA	United States Of America	21 Mar 2006	78851363			Pending	Biovail Laboratories International SRL	
T029-CA-NF	ONELZA	Canada	29 Sep 2006	1318518			Pending	Biovail Laboratories International SRL	
T029-US-NF	ONELZA	United States Of America	31 Mar 2006	78851346			Pending	Biovail Laboratories International SRL	
T031-BB-NF	ONEXTEN	Barbados	10 Sep 2008	81/25090			Pending	Biovail Laboratories International SRL	
T031-US-NF[2]	ONEXTEN	United States Of America	24 Oct 2008	7759980			Pending	Biovail Laboratories International SRL	
T032-US-NF	ORAMELT	United States Of America	08 Aug 2002	76439672			Pending	Biovail Laboratories International SRL	
T051-BB-NF	ORAMELT	Barbados	28 Aug 2006	81/22151			Pending	Biovail Laboratories International SRL	
T100-US-NF	ORAMELT	United States Of America	11 Aug 2008	77/543,711			Pending	Biovail Laboratories International SRL	
T030-CA-NF	PALVATA	Canada	29 Sep 2006	1318525			Pending	Biovail Laboratories International SRL	
T030-US-NF	PALVATA	United States Of America	17 Apr 2006	78862931			Pending	Biovail Laboratories International SRL	
T053-BB-NF	RALIVIA	Barbados	30 Aug 2006	81/22157			Pending	Biovail Laboratories International SRL	
T053-CA-NF	RALIVIA	Canada	12 Sep 2006	1316182	04 Dec 2008	730180	Registration	Biovail Laboratories International SRL	

BOS111 12386775.4

PATENT

Error! Unknown document property name.

-Biovail Case Reference	Trademark	Country	Filing Date	Filing Number	Registration Date	Registration Number	Current Status	Registered Owners	Notes
T096-BB-NF	SHEARFORM	Barbados	05 Feb 2008	81/24155			Pending	Biovail Laboratories International SRL	
T096-CA-NF	SHEARFORM	Canada	29 Jul 2008	1405335			Pending	Biovail Laboratories International SRL	
T096-US-NF	SHEARFORM	United States Of America	06 Feb 2008	77/390719			Pending	Biovail Laboratories International SRL	
T035-US-NF	SMARTCOAT	United States Of America	08 Sep 2003	78297563			Pending	Biovail Laboratories International SRL	
T050-BB-NF	SMARTCOAT	Barbados	28 Aug 2006	81/22150			Pending	Biovail Laboratories International SRL	
T025-CA-NF	SOLBRI	Canada	29 Sep 2006	1318526			Pending	Biovail Laboratories International SRL	
T025-US-NF	SOLBRI	United States Of America	17 Apr 2006	78862981			Pending	Biovail Laboratories International SRL	
T037-CA-NF	TESIVEE	Canada	29 Sep 2006	1318513			Pending	Biovail Laboratories International SRL	
T037-US-NF	TESIVEE	United States Of America	31 Mar 2006	78851273			Pending	Biovail Laboratories International SRL	
T038-US-NF	TIAZAC	United States Of America	05 Nov 1993	74454789	23 Jul 1996	1988853	Registration	Biovail Laboratories International SRL	
T061-CA-NF	TIAZAC	Canada	17 May 1995	0783048	25 Nov 1997	486200	Registration	Biovail Laboratories International SRL	
T075-HK-NF	TIAZAC	Hong Kong	23 May 2007	300875700			Pending	Biovail Laboratories International SRL	
T088-CN-NF	TIAZAC	China	18 Jun 2007	6114273			Pending	Biovail Laboratories International SRL	

BOS111 12386775.4

PATENT

Biovail Case Reference	Trademark	Country	Filing Date	Filing Number	Registration Date	Registration Number	Current Status	Registered Owners	Notes
T092-CO-NF	TIAZAC	Colombia	04 Oct 2007	07-104259			Pending	Biovail Laboratories International SRL	
T095-TW-NF	TIAZAC	Taiwan	31 May 2007	096025872			Pending	Biovail Laboratories International SRL	
T098-US-NF	TITRADOSE	United States Of America	13 Feb 2008	77396172	31 Mar 2009	3597399	Registration	Biovail Laboratories International SRL	
T039-US-NF	TOVALT	United States Of America	04 Apr 2003	76504006			Pending	Biovail Laboratories International SRL	
T052-BB-NF	TOVALT	Barbados	30 Aug 2006	81/22158			Pending	Biovail Laboratories International SRL	
T067-CA-NF	TOVALT	Canada	12 Sep 2006	1316184			Pending	Biovail Laboratories International SRL	
T090-US-NF	TOVALT	United States Of America	14 Aug 2007	77254549			Pending	Biovail Laboratories International SRL	
T040-US-NF	UPZIMIA	United States Of America	04 Apr 2003	76504005			Pending	Biovail Laboratories International SRL	
T093-BB-NF	UPZIMIA	Barbados	21 Aug 2007	81/23563			Pending	Biovail Laboratories International SRL	
T093-CA-NF	UPZIMIA	Canada	21 Feb 2008	1384285			Pending	Biovail Laboratories International SRL	
T093-US-NF	UPZIMIA	United States Of America	30 Jan 2008	77/383919			Pending	Biovail Laboratories International SRL	
T041-US-NF	UPZIVA	United States Of America	04 Apr 2003	76504007			Pending	Biovail Laboratories International SRL	
T042-US-NF	VASERETIC	United States Of America	09 Oct 1984	73503117	14 May 1985	1335085	Registration	Biovail Laboratories International SRL	

BOS111 12386775.4

PATENT

-Biovail Case Reference	Trademark	Country	Filing Date	Filing Number	Registration Date	Registration Number	Current Status	Registered Owners	Notes
T043-US-NF	VASOCARD	United States Of America	20 Aug 2004	78471082			Pending	Biovail Laboratories International SRL	
T044-US-NF	VASOTEC	United States Of America	15 Feb 1984	73465852	16 Jul 1985	1348858	Registration	Biovail Laboratories International SRL	
T045-CA-NF	VEMRETA	Canada	29 Sep 2006	1318514			Pending	Biovail Laboratories International SRL	
T045-US-NF	VEMRETA	United States Of America	31 Mar 2006	78851392			Pending	Biovail Laboratories International SRL	
T046-CA-NF	VOLZELO	Canada	29 Sep 2006	1318520			Pending	Biovail Laboratories International SRL	
T046-US-NF	VOLZELO	United States Of America	31 Mar 2006	78851320			Pending	Biovail Laboratories International SRL	
T017-US-NF	ZILERAN	United States Of America	17 Nov 2004	78518422			Pending	Biovail Laboratories International SRL	

BOS111 12386775.4

Error! Unknown document property name.

SCHEDULE C

REQUIRED CONSENTS AND LICENSES

None.

BOS111 12386775.4

Error! Unknown document property name.

PATENT
REEL: 022813 FRAME: 0258

SCHEDULE D

CLAIMS, LITIGATION, ETC.

None.

SCHEDULE E

NOTICE ADDRESS FOR THE GRANTOR

Biovail Laboratories International SRL

Welches

Christ Church, Barbados BB17154

SCHEDULES

Schedule A	Patents
Schedule B	Trademarks & Service Marks
Schedule C	Required Consents & Licenses
Schedule D	Claims, Litigation, Etc.
Schedule E	Notice Address for the Grantor

BOS111 12386775.4

Error! Unknown document property name.

RECORDED: 06/11/2009

PATENT
REEL: 022813 FRAME: 0261